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Qatar has a modern public and private healthcare system, and the state provides the majority of 
healthcare services free to its citizens. The aim of this study was to identify priority medicines 
policy issues, including the “use” and “access to medicines” in Qatar. In this qualitative study, 
opinions and knowledge about priority medicines policy issues in Qatar were explored. Fifty-five 
stakeholders in Qatar were contacted by face-to-face meetup, email, WhatsApp, and phone calls. 
Out of 55, 21 agreed to participate and they were from healthcare practices and academia. The 
recruitment method involved meeting with key stakeholders and using a snowball sampling 
procedure. The inclusion criteria included: (a) participants working or involved in Qatar’s 
healthcare system for more than five years; (b) participants having experience or working 
knowledge of medicines policy, or different facets of medicines policy, use and access to 
medicines; and (c) participants well versed in the English language.   
All participants were involved in semi-structured, audio-recorded interviews, which were then 
transcribed verbatim, coded and followed by thematic analysis to identify the common themes. 
The identified themes include (a) Defining Medicines Policy (b) Access to Medicines (c) Use of 
Medicines (d) Future Overall Health and Use of Medicines for Qatar. This study found challenges 
related to the availability of pharmaceuticals in Qatar, including the medicines registration 
process.  
There is no comprehensive national medicines policy in Qatar, however, there are a number of 
rules, regulations, policies and procedures in place. The community pharmacy services provided 
are mostly “traditional” with little emphasis on pharmacists’ extended roles and /or cognitive 
services. The study identifies several areas for improvement including extending the role of the 
pharmacist, improving the prescribing of antibiotics, medicines compliance and counselling for 
consumers, pharmacovigilance and implementation of generic medicines policies, as well as the 
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As of 2020, the population of Qatar is 2.79 Million.[1] Qatar has a public and private healthcare 
system and provides modern healthcare services to its nationals and residents. The quality of 
healthcare in Qatar is very high.[2] The Qatar National Vision 2030 (QNV 2030), started in July 
2008, has four pillars, including (a) economic development, (b) social development, (c) human 
development and (d) environmental development.[3] In 2011, the first National Development 
Strategy (NDS-1) was developed so that the Qatar National Vision 2030 goals could be achieved. 
The State of Qatar started its National Health Strategy 2018-2022 (Q-NHS 2018) in 2018 and the 
aim was to develop a comprehensive world-class healthcare system.[4] The vision of Q-NHS 2018 
is to build the expansion of health services, and provide improvements in health and healthcare 
for everyone living in Qatar.[3, 5, 6]  The Qatar NHS aims to achieve better health care and better 
value for all. The Qatar National Health Service (NHS) is led by the Ministry of Public Health, and 
the objective is to guide the healthcare system in Qatar.[6] The vision of Q-NHS is "Our Health 
Our Future" and is based on seven principles.[6] 
The Q-NHS has 12 priority areas, including seven priority populations and five system-wide 
priorities. It is projected that Qatar will spend QAR 18.8 billion (USD5.2 billion) in 2020 on 
health.[5, 7] The seven principles of Qatar NHS 2018-2022 are action and empowerment, 
teamwork and collaboration, patient-centred care, accountability, patient safety, leadership, 
intelligence and empathy. The Qatar NHS population priorities are Healthy Children and 
Adolescents, Healthy Women Leading to Healthy Pregnancies, Healthy and Safe Employees, 
Mental Health and Well-being, Improved Health for People with Multiple Chronic Conditions, 
Health and Wellbeing for People with Special Needs and Healthy Ageing. The system-wide 
priorities are an Integrated Model of High-Quality Care and Service Delivery, Enhanced Health 
Promotion and Disease Prevention, Enhanced Health Protection, Health in All policies, and an 
Effective System of Governance and Leadership.[6]  
There are seven Supporting Strategies and Frameworks for the Qatar NHS, including the Qatar 
Public Health Strategy, National Primary Health Strategy, National Diabetes Strategy, Qatar 
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National Dementia Plan, National E-Health and Data Management Strategy, Continuing Care 
Design Strategy and Qatar Health Facility Master Plan.[6]  
1.1 Qatar Health and Health Problems 
Qatar's population in May 2020 was 2.8 million, of which 73% are male and 27% female. Of 2.8 
million people, 80% are expatriates and 20% Qatari nationals.[8] In Qatar, 11% of the population 
is aged between 15 and 25 years, 74% is aged between 25 and 65, and only 1% of the population 
is older than 65.[8] Qatar has a young population and expatriates from around the world, bringing 
multicultural beliefs and practices. 
 Wilbur et al. (2019) report that the State of Qatar provides healthcare services free of charge to 
all Qatar nationals.[9] The expatriates have subsidized healthcare services in the public sectors, 
and they only pay 20% of the cost of pharmaceuticals. Qatar is developing a healthcare system 
according to world-class standards to enhance the health of Qatari nationals and residents. The 
intentions are to enhance the health and extend the life expectancy of its population. All 
healthcare services are expected to be accessible and affordable to the all-inclusive population 
irrespective of nationality.[10, 11] Private healthcare in Qatar is through patient insurance, or 
otherwise, patients have to pay for services and products.[9, 12]  
Qatar's most common diseases are Non-Communicable Diseases (NCD), including cardiovascular 
diseases (CVD), diabetes, cancer and chronic respiratory diseases. In Qatar, 69% of the people 
have cardiovascular disease, diabetes and cancer, 70% of Qatari adults are overweight, and 43.9 
% of the population have a low level of physical activity. Around 88% of Qatari children have 
dental cavities, and the estimated tobacco usage among men is 31.9% while among women, it is 
1.2 %.[13-16]  
In Qatar, there are 3.3 physicians for every 1,000 people. The ratio of healthcare providers is 7.5 
for nurses, 0.6 for dentists, 1 for pharmacists and 3.5 for the other healthcare providers.[17] 
There are 1.3 hospital beds per 1,000 population. As of 2018, there were 327 private pharmacies 
in Qatar.[17] The most common cause of mortality in Qatar is cardiovascular diseases, including 
hypertension, diabetes and cholesterol, which accounted for 33.1% deaths during 2018,[18] 
while 16.6% of deaths were due to road accidents, falls, drowning, exposure to smoke, fire and 
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flames, and toxic substances, self-harm and assault. The third cause of mortality is neoplasms, 
which is responsible for 15.1% of deaths. The fourth reason is respiratory system diseases, and 
these are responsible for 11% of total deaths in Qatar.[18]  
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Table 1. Qatar morbidity and mortality status and health workforce 
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1.2 Qatar's National Medicines Policy 
The State of Qatar has a National Health Strategy 2018-2022, which focuses on twelve priority 
areas and seven Support Strategies and Frameworks. The Support Strategies and Frameworks 
include the Qatar Public Health Strategy 2017-2022 and National Primary Health Strategy. The 
goal is to develop a comprehensive world-class healthcare system.[4] The MoPH is leading NHS 
2018-2022, and the NHS is an all-encompassing vision for Qatar's health sector. In 2011, the State 
of Qatar launched its first edition of a National Health Strategy (NHS 2011), summarizing a 
comprehensive programme. The NHS 2011 was started to reform advanced patient-centred 
health services in all hospitals and clinics under the umbrella of Qatar National Vision 2030.[19]  
Qatar’s National Medicines Policy 
The National Medicines Policy of a country provides guidance regarding the quality, safety, 
effectiveness, access and use of medicines.[20] There is a need for a generic medicines policy and 
guidelines in Qatar.[21] The government is supporting the use of generic medicines,[22] but it 
seems that Qatar does not have an official document named Qatar’s national medicines policy. 
However, there is a set of regulations, policies and strategies related to medicines. These 
documents govern the use of and access to medicines in Qatar.[23]  
The Pharmacy and Drug Control Department (PDCD) of MoPH recommends the medicines policy, 
developing pharmaceutical care, authorizing laws and regulations, governing the pharmacy 
profession, and registering medicines, pharmaceutical companies and factories in Qatar. The 
PDCD has four departments and sections, which are (1) Registration and Drug Pricing, (2) Quality 
of Medicines Laboratories, (3) Inspection and Narcotics and (4) Pharmacist Release.[24, 25]  
The PDCD abides by the laws and regulations of the Ministry of Foreign Affairs in Qatar for 
narcotic and psychotropic substances. Law No. 9 of 1987 is on the Control and Regulation of 
Narcotic Drugs and Dangerous Psychotropic Substances (NDDPS), while medicines pricing is 
governed by Law No. 1 of 1999 Amending Certain Provisions of Law No. 7 of 1990, Regulating 
and Controlling the Pricing of Medicines and Pharmaceuticals 1 / 1999.[26-28]  
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1.3 Pharmaceuticals and Pharmacy Systems 
The pharmaceutical sector and public healthcare are governed by MoPH, including public and 
private pharmacies and medication warehouses.[9] In 2019, Qatar spent QAR 2.4 billion (USA 657 
million) on medicines.[29] It is estimated that the prescription drug market will increase in the 
future due to demand for access to healthcare and increases in non-communicable diseases.[29] 
Qatar has public and private pharmacy systems. The Ministry of Public Health (MoPH) is 
responsible for Hamad Medical Corporation (HMC) pharmacies in hospitals. In the private sector, 
most hospitals and clinics have their own pharmacies, and there are companies with their own 
chain pharmacies and independent pharmacies. As of Sept 2017, there were 1.8 pharmacies per 
10,000 population.[30] 
1.4 Import of Medicines  
The State of Qatar's pharmaceuticals sector is very much dependent on the import of 
pharmaceutical products. The pharmaceutical expenditure projection was estimated to be at 
USD 657 million in 2019 and USD 696 million in 2020. The Ministry of Public Health (MoPH) is 
willing to eliminate government controls over medicines pricing and to allow more imported 
medicines into Qatar.[10] Medicines are imported from many international pharmaceutical 
companies, for example, Roche, MSD, GSK, Novartis, Sanofi and AstraZeneca.[11] Although there 
is no government policy on the bioequivalence of generic medicines,[31] the government is 
promoting the use of these. Qatar Pharma is the leading local manufacturer in the country.[32]  
The Gulf Cooperation Council (GCC) states formed a Gulf Centralised Committee for Drug 
Registration (GCC-DR) to improve imports of and access to medicines in May 1999. The GCC-DR 
consists of Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, the United Arab Emirates and Yemen.[33, 
34] After the Qatar blockade in 2017, most importers of medicines followed a procurement 
process without GCC-DR. In the State of Qatar, the highest drug authority is the Pharmacy & Drug 
Control Department (PDCD). Under the Ministry of Public Health (MOPH), the PDCD is 
responsible for ensuring the quality, safety and efficacy of any health product in Qatar.[35]  
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Local Manufacturing 
Qatar Pharma began pharmaceutical production in 2009 in Qatar.[36] QLife Pharma is another 
domestic pharmaceutical manufacturing company which started in 2016 and is working to get US 
FDA approval of its drug products.[37] Other pharmaceutical companies include Qatar Al-Hayat, 
Q-Med; Al-Mutamayyiz Factory for pharmaceutical products, and Doha Factory for 
pharmaceutical products. There is a need to reduce dependence on imported pharmaceuticals 
[32, 38] and there are additional new local pharmaceutical manufacturers, including the Qatar 
Pharmaceutical Industries Company.[39]  
1.4.1 Use of Medicines 
The World Health Organization (WHO) recommends that the effective implementation of a 
medicines policy could increase the responsible use of medicines.[40]  This could have a positive 
impact on medicines spending, patient health outcomes and medicines adherence. The use of 
medicines is an essential element of a country’s national medicines policy.[40]  
Aljayyousi et al. (2019) report the significant inappropriate antibiotic use in Qatar.[41] Eighty-two 
percent of the consumers were using medicines without a prescription, 45% did not complete 
the antibiotic course, and 23% were taking antibiotics from the pharmacy without a prescription. 
[41] It was observed that 85% of people in Qatar use antibiotics for upper respiratory tract 
infections.[41-43] Also, Jaam et al. (2018) found that patients with uncontrolled diabetes have a 
significantly higher medication nonadherence rate in Qatar.[44] This study concluded that there 
is a need to implement interventions to improve medicines adherence.  
Abdulrhim et al. (2019) concluded that collaborated pharmaceutical care services and 
pharmacists’ interventions would improve clinical outcomes in type 2 diabetes mellitus patients 
in Qatar.[45] The country also faces myriad challenges with regards to the use of medicines as 
more than 80% of the population is migrant.[46] Hence the migrant face challenges with regards 
to medicines access and use. This has also been seen in other countries where there is a migrant 
population. For example, Babar et al. (2013) have identified substantial difficulties in the use of 
medicines among the migrants' population in New Zealand.[47, 48]  
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1.4.2 Access to Medicines 
Access to medicines is an essential element of pharmaceutical policy, including equitable access, 
availability and affordability of medicines, as well as cost-effective use of medicines.[49] Qatar’s 
public hospitals and clinics provide free healthcare services for Qataris and subsidized healthcare 
and pharmaceutical services for expatriates.[9] In Qatar, multinational pharmaceutical 
companies have been successful in promoting more brand name consciousness for patients and 
physicians. This is for both prescription and over-the-counter medications.  
Qatar imports medicines mainly from western countries, including Europe, UK, the USA and a 
small proportion from other countries. There are few challenges with regards to the registration 
and licensing of medicines in Qatar. This includes tender regulations, procurement processes, 
unpredictable consumption trends and physicians’ preferences.[50] The availability of medicines 
is also affected by the time required to imports medicines in Qatar. 
The regulatory review process of medicines involves 13 critical steps in Qatar which affect the 
processing time and cause delays in access.[34] The medicines registration process also impacts 
generic drug registration processes. On the other hand, generic manufacturers could have good 
business opportunities because by using generic medicines, Qatar can reduce its healthcare 
expenditure.[11]  
The prices of medicines have been reduced by MoPH in recent years. Of 4600 registered 
medicines, the prices of 2873 (62.5%) have been reduced.[29] Globally it has been observed that 
a Generic Drug Policy (GDP) is an integral part of medicines policy, and it can be effective in 
reducing pharmaceutical expenditures.[51, 52]  
Access to medicines can be improved by sharing information and experiences about policy 
implementation and procurement, including challenges. This is very valuable for countries. There 
is also strong evidence to use generic medicines, which can result in prices reduction, savings, 
and improves access overall. [53] Qatar can improve saving on the healthcare budget by learning 
lessons from other counties, especially GCC, and using generic medicines. An Australian study 
concluded that some patients did not fill prescriptions because of costs and due to high co-
payments. Those patients are the least adherent patients.[54] Therefore prescription costs are 
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linked with medicine adherence.[55] Access to medicines can also be improved with new 
knowledge related to pharmaceutical technologies, and electronic health records data.[56, 57] 
 
Moreover, World Health Organisation (WHO) stated that access to essential medicines and 
vaccines remains to be a challenge in many countries. WHO developed a new strategy to focus 
on the challenges identified in providing access to safe, effective, affordable, and sustainable 
supplies of medicines and vaccines.[58] Medicines shortage was also identified as a major 
concern. There could be many reasons for medicines shortages and is prevalent globally including 
in Europe. A study in Europe observed that about 75% of respondents reporting weekly or daily 
medicine shortages.[59]. That affects the patient's access to medicines . This could also lead to  
adverse health outcomes, medication errors, as well as economic consequences for patients.[60] 
 
1.5 Rationale of the Study  
Medicines policy is an essential component of a country’s healthcare system.[61, 62] Qatar is a 
country with a small population, and it has its own set of pharmaceutical-related challenges. This 
is in terms of both medicines use and access, as well as for a forward-looking approach. Qatar 
imports most of its medicines; hence there are issues related to pricing, medicines registration, 
as well as access and availability of medicines.[10, 63]  
The rationale of this study is to identify broad medicines policy and pharmaceutical health system 
issues. Access to medicines is one such issue. Qatar imports most of it’s medicines. As the 
medicines are imported, the prices are on the higher side, the taxes are added and there are also 
additional logistics and transportation costs. Moreover, the imported medicines registration 
process may take few months, which may affect access, availability, and affordability of 
medicines. Due to the reasons above WHO has favored the local production of medicines as it 
can improve the access and affordability of medicines. [64,65] 
It is vital to identify priority medicines policy issues in a country so that better-informed medicine 
policies can be built. Several developed countries, including Australia and New Zealand, have 
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benefited from the development of priority medicines policies. This includes building cost-
effective medicines policies.[66] Babar and Francis identified priority medicines policy issues for 
New Zealand, and [67] Mirza discussed the need to identify priority medicines policy issues for 
Saudi Arabia.[68]  
Priority medicines is a terminology that is being borrowed from the 2013 WHO document. It has 
been further refined with Babar and Susan (2014).[67,69] This is linked to medicines policy issues 
identified in a country due to local disease burden and gaps in the health system.  
Hence, in this context, this study has been planned to explore and get an understanding of 
priority medicines policy issues for Qatar. Determining and synthesizing priority medicines policy 
issues can provide a future direction towards medicines policy, access and use questions in the 
country. The study is conducted by exploring the opinion of stakeholders about priority 
medicines policy issues in Qatar.  
Qatar National Vision 2030 (QNV2030) and National Health Strategy (Q-NHS) 2018-2022 
recommends “Health for All”. Moreover, this strategy also focused on better health outcomes. 
National medicines policies in a country also promote better health outcomes through the 
appropriate and responsible use of medicines. This study identifies the priority medicines policy 
issues that support the Q-NHS and Qatar National Vision 2030. 
1.6 Objectives 
The research aims to identify priority medicines policy issues for Qatar. The specific objectives 
are as follows: 
1. To explore and identify key challenges affecting Qatar in terms of priority medicines policy 
issues, including medicines use and access. 
2. To explore the futuristic approach in terms of overall medicines access and use in Qatar. 
The study objectives are linked to medicines policy issues identified in a country due to local 
disease burden and gaps in the health system.[67] 
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CHAPTER 2 
2 Literature Review  
The following is a synthesis of the studies and literature on this topic. 
2.1 Literature Search 
A review of the literature published between January 2000 and June 2020 in the English language 
was performed from February 2019 to June 2020. It included studies, full-text articles, journal 
articles, reports and book chapters. The objective was to find all literature available on medicines 
policy issues, access to medicines and use published on Qatar. The keywords used were 
medicines policy, pharmaceutical policy, drug policy, medicines strategy, pharmaceutical 
strategy, drug strategy, medicines policy issues, access to medicines and use, affordability and 
availability, and Qatar.[70] The primary databases used were Scopus, Science Direct, Medline, 
PubMed and Google Scholar, book chapters were also reviewed.[52, 71, 72]  
The global and local literature review cover key areas related to medicines policy, access to and 
use of medicines. It also covers issues related to medicines shortages, imports, pricing, licensing, 
medicines adherence, and counselling. This collectively feeds into identifying the gaps in 
medicines policy literature in the country. It also helps to frame the objectives and research 
question for this study, which is to "identify priority medicines policy issues ". An exploratory 
qualitative design is used to uncover stakeholders' opinions as no formal medicines policy 
document is available in the country. 
Synthesis of Literature Review 
2.1.1 Medicines Policy 
A national medicines policy is vital for the health system, as described by Almarsdóttir et al. 
(2019).[61] A medicines policy is a comprehensive national framework that focuses on and 
explains difficulties related to medicines. It provides guidelines for all the critical sectors in the 
pharmaceutical field, comprising both public and private sectors. The medicines policy sets goals 
for the government and all healthcare sectors, including the pharmaceutical sector, and pinpoints 
both general and the most critical strategies for those goals.[61]  
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Medicines policy covers medicine development, manufacturing, marketing, distribution, pricing 
and reimbursement, formulary management, pharmacovigilance, patient eligibility, prescribing 
practice and professional services, particularly pharmaceutical services.[73] Al-Essa et al. (2015) 
describe the foundation of any country's medicines regulation as a "national drug policy."[74] 
This will guarantee a sustainable pharmaceutical industry and benchmark medicines 
authorization process.[34, 74] Additionally, Ibrahim et al. (2017) state that in low-and middle-
income countries (LMICs), there are high prices, low-quality medicines and lack of medicines 
access despite support from international agencies like the World Health Organization 
(WHO).[75] The Sustainable Development Goals (SGDs) of the World Health Organization (WHO) 
include four key components, including use of essential medicines, development of national 
standard treatment guidelines and a National Essential Medicines List (EML). A second 
component refers to affordability and availability, including access to essential medicines, use of 
unbiased available price information, allowing price competition, supporting bulk procurement, 
implementing generics policies, negotiating fair pricing and promoting local production of quality 
medicines. Another component considers sustainable financing, including a reduction in out-of-
pocket expenditures, increased public funding, expansion of health insurance schemes, and 
exploration of external funding and financing mechanisms.[76, 77]  
The medicines policy governs and manages marketing authorization, inspection and surveillance 
of market actors, pharmacovigilance, advertisement, provision of independent medicines 
information, and also deals with ensuring affordable access to medicines for patients.[78]  
Norman (2015) describes three significant elements to pursuing pharmaceutical policy: effective 
skills, practical use of current systems to improve participation with policymakers and focusing 
on vital areas that improve health outcomes.[68]  
A study by Newton et al. (2020) describes the need to control substandard and falsified medical 
products. Hence, Newton argues the need for “Effective regulatory supervision, robust 
authentication measures, and procurement policies supporting quality, as well as the need for 
trusted public engagement campaigns.”[80] Additionally, Hafner et al. (2020) conclude that 
global public health issues like HIV and TB, and in recent times COVID-19, have emphasized the 
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importance of public health policies and must include plans for disease-specific programmes 
focusing on health outcomes and sustainable health systems.[81] Almarsdottir et al. (2019) also 
describe how pharmacy practice has been affected by national medicines policies, and the 
pharmacist has a vital role to play.[61] Pharmacists are active in healthcare; for example, they 
have developed pharmaceutical care services to improve pharmacy clinical services.[61, 82]  
In 1998, the World Health Organization developed a document on National Medicines Policies 
(NMP), which was further revised in 2001. The document emphasized that governments should 
prioritize, develop and have an implementation plan for National Medicines Policies.[40, 83, 84] 
Wirtz et al. (2017) reported that by 2015, there were 95 countries who had developed a National 
Medicines Policy.[85] The components of a National Medicines Policy are discussed below based 
on findings from the literature. 
2.1.1.1 Medicines supply chain and pricing  
The World Health Organization has provided different stages for governments to control the 
pharmaceutical supply chain and recommend eight (8) methods to impact the manufacturers' 
prices. These are as follows: “(1) Price controls on the manufacturer; (2) Profit controls on the 
manufacturer; (3) Reference pricing and brand premiums; (4) Comparing pricing controls 
(international benchmarking); (5) Eliminating tariffs and taxes; (6) Fixed margins; (7) Digressive 
mark-ups; and (8) Capitation systems."[23] 
Breen et al. (2020) have identified the risks for medicines supply chains, and the five most 
common risks are (1) fragmentation of Supply chain—no single source, multiple channels, no 
communication, unilateral decisions; (2) lack of visibility of stock; (3) unexpected increase in 
demand; (4) demand versus capacity; and (5) information flow or lack of information.[86]  
2.1.1.2 Medicine prices in Qatar 
In Qatar, The Ministry of Public Health (MoPH) controls medicine pricing. The Pharmacy and Drug 
Control Department (PDCD) negotiates with pharmaceutical companies and other stakeholders 
to propose medicines for reimbursement, which are then authorized by the Ministry of Finance. 
Qatar has applied a free-market system to manage the high prices of medicines and guarantee a 
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better supply chain for all registered and licensed importers. The MoPH fixes prices of medicines 
at private pharmacies against the council's initial price control mechanisms.[10] The public and 
private sectors have different purchasing and pricing processes. The public sector is publicly 
funded, and medicines are acquired via various channels. This is mainly by Gulf Cooperation 
Council (GCC) bulk procurement, agreements directly with local manufacturers, or local agents. 
The medicines pricing method in the public sector is not publicly available; however, prices of 
medicine have been found to be considerably lower in the public sector as compared to the 
private sector.[23] 
Abdel Rida et al. (2019) concluded that pharmaceutical pricing in Qatar is primarily established 
on external reference pricing (ERP) and mark-up regulations.[23] Qatar may take into account 
the economic evaluation and therapeutic importance of medicine to set the price.[23, 87] 
However, in other counties, medicines pricing policies have not been successful because of 
inadequate administration of regulation, absence of governance, low monitoring, corruption and 
a lack of full compliance with the stakeholders.[88] 
Vogler (2018) suggests that the policymakers should consider a range of measures when 
developing pricing policies, including (1) a mix of pricing policies; (2) enforcement; (3) evaluation 
and reviews; and (4) transparency.[78, 89] Hasan et al. (2018) argue that High-Cost Medicines 
(HMCs) coverage should be built on an evidence base and pharmacoeconomic analysis, with all 
stakeholders participating in the evaluation.[90] 
2.1.2 Access to Medicines 
High price medicines are a challenge for most countries. Babar et al. (2019) point out that high 
prices of new cancer medicines affect access to medicines, and it is also observed that the prices 
of the same cancer medicines in high-income countries show a big price differential.[91] Hasan 
et al. (2019) explain that all high-cost medications present health and economic challenges for 
healthcare organizations and may involve issues regarding affordability and critical decision-
making for coverage and reimbursement.[92] Nowadays, healthcare software appraisal has also 
become a crucial health policy tool for decision-making and controlling high-cost medications. By 
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using these health technology assessments, patients’ access to cost-effective treatment can be 
made feasible.[92]  
2.1.2.1 Generic medicines and biosimilars in Qatar 
A community pharmacy study in Qatar has found that 89% of pharmacists agreed that "Health 
authorities in Qatar should implement bioequivalence policies before a generic product is 
marketed." The majority of the respondents also agreed that "Community Pharmacists should be 
allowed to perform generic substitution without consulting the prescribing physician."[31] 
Awaisu (2014) concluded that a large percentage of community pharmacists in Qatar had basic 
knowledge about generic medicines; however, they do require knowledge on practical and 
regulatory aspects of bioequivalence and pharmacokinetics.[31] The study also showed that a 
training programme should be established to improve the quality and uptake of generic 
medicines in Qatar. Rehman et al. (2018) and Khan (2019) state that the biosimilars provide more 
treatment options and possible cost savings in healthcare.[93, 94, 95] The new generation of 
biologicals or biosimilars is also available in the global market. However, prescribing of biosimilars 
should be evidence-based. All the above studies conducted in Qatar showed that there is a need 
to establish a generic medicine policy for the country. 
2.1.2.2 Community pharmacies and access to medicines in Qatar 
Wilbur et al. (2019) discussed access to medicines and community pharmacies in Qatar.[9] The 
community pharmacy services are mostly "traditional" with no pharmacists having extended 
roles or cognitive services. However, community pharmacy has not developed the essential steps 
to be recognized as an essential source for public health and primary health care in Qatar. Ibrahim 
et al. (2016) report that the community pharmacists in Qatar spend little time providing 
counselling with an average of two to three minutes, whereas the literature suggests that the 
appropriate length of time for providing counselling should be longer than this.[96] In addition, 
Jaam et al. (2018) identified that the rate of medication nonadherence, including patients with 
uncontrolled diabetes, is significantly high.[44] This study emphasises that there is a need for 
targeted implementation strategies to increase medication adherence in high-risk patients in 
Qatar.  
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2.1.3 Use of Medicines 
2.1.3.1 Use of medicines issues 
Babar and Scahill (2017) point out that the use of medicines is an essential area for patients, 
consumers and healthcare professionals.[97] Use of medicines studies and research areas include 
perceptions, beliefs, knowledge and attitudes, as well as studies on medication adherence, 
prescribing, dispensing, concordance and compliance. Globally, antibiotic resistance is growing 
due to the increase in patients’ stays in hospital. This means an increase in operations-related 
infection and a substantial increase in healthcare costs.[98] Shaikhan et al. (2018) concluded that 
antimicrobials are commonly overprescribed in all areas.[99] This study will assist policymakers 
in improving the use of antimicrobials. Alkhuzaei et al. (2015) show that the physicians and 
pharmacists of the Primary Health Care Corporation (PHCC) in Qatar provide satisfactory 
antibiotic use consultation.[100]  
Babiker et al. (2014) concluded that the pharmacists in Qatar have adequate information about 
medicines use, though there are some areas that need further improvement.[101] El-Hajj et al. 
(2018) report that the pharmacists in Qatar provide primary care for diabetic patients and 
provide limited advanced diabetes services.[102] However, they need more training and 
education for better provision of these services. The common challenges in this respect are 
identified to be time and availability of private counselling areas.[101-103] Bain et al. (2019) 
describe how pharmacists could help to improve insulin ordering in hospitals by reviewing 
prescriptions and using decision-support resources, for example, algorithms and prescribing 
charts, electronic prescribing software and evidence-based guidelines, all of which would help 
improve patient safety.[115] Sonallah et al. (2017) suggest that medication reconciliation by 
pharmacists reduces medication errors, as most medication discrepancies happen on hospital 
admission.[105] 
2.1.3.2 Challenges regarding the use of medicines 
Aljayyousi et al. (2019) reports that while some study participants in Qatar thought physicians 
and pharmacists were giving sufficient patient education about proper antibiotic use, half of the 
participants stated that physicians and pharmacists did not give enough time to explain the 
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proper use of antibiotics.[41] Hamid and Ibrahim (2017) emphasise the need for a 
digitized/electronic interconnected transparent regulatory structure and pharmacovigilance (PV) 
programmes to improve medicines safety.[106] They argue that data could be missed when using 
paper-based documentation. Al-Essa et al. (2015) explain that the regulators require the 
pharmaceutical sector to comply with regulatory obligations before and after medicines are 
made available for patients and consumers. Also, in order to monitor medicines’ safety and 
efficacy, continuous follow up with the pharmaceutical industry is needed.[107]  
Qatar’s healthcare reforms could improve pharmacovigilance practices with greater 
accountability and transparency, and through the useful implementation of policies and 
regulations.[106, 108] Alshammari et al. (2019) describe how the Pharmacy and Drug Control 
Department (PDCD) is regulating medicines and working to develop the pharmacovigilance 
programme in the State of Qatar.[109] There is an Adverse Drug Reaction (ADR) programme 
organized by the Medication Safety and Quality Center (MSQC) at the Hamad Medical 
Corporation (HMC).[109, 110] Abdelrahman et al.’s (2015) study also shows that the most 
common paediatric accidental poisoning cases reported were through the use of analgesics and 
antipyretics among children one to five years old.[111] This also highlights the need for a 
systematic and structured training programme covering the fundamental aspects of Medicines 
Use Review (MUR) services in Qatar.[101]  
Ibrahim et al. (2016) concludes that community pharmacists provide sub-optimal medicines 
dispensing services, including insufficient time spent on patient counselling, providing limited 
knowledge about the use of medicines, and dispensing too many antidiarrheals and 
antimicrobials.[96] Their general practices were also found to be lower than expected. 
Furthermore Rouf et al. (2018) state that in Qatar, a pharmacist has only an average knowledge 
about the use of medicines in pregnancy, and there is a need to introduce continuous education 
programmes about this.[112]  
Additionally, El-Hajj et al. (2014) reports that pharmaceutical care service providers identified the 
obstacles as lack of access to medical records, availability of time and a poor image of pharmacists 
in society.[113] Furthermore, Stewart et al. (2018) describe issues with Qatar's patient safety 
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culture.[114] This indicates that there is a need for improvement. This should be done at the 
organizational policy level and not focused only at the level of individual practitioners. The goal 
should be to improve the patient safety culture.  
Aljayyousi et al. (2019) suggests that in Qatar, health educators should develop focused 
awareness promotions to educate the public about the proper use of antibiotics, the effects of 
antibiotics misuse and the difference between bacterial and viral infections.[41] Awareness 
should be raised and there should be a focus on changing attitudes and behaviours through 
various behavioural interventions. Additionally, the healthcare organizations in Qatar should 
offer advanced education for healthcare providers. These are the ones who have the authority 
to prescribe antibiotics, to improve antibiotic prescribing and to improve health professionals’ 
communication methods. The government should emphasise the regulations and guidelines to 
improve prescribing and dispensing of antibiotics.[41] 
2.2 Future Overall Health 
In 2007, the World Health Assembly (WHA) identified that health technologies are essential 
instruments for preventing, diagnosing, treating, rehabilitating and agreeing on health-related 
development goals.[115] The WHA report said that health technologies are both a technical and 
financial challenge to health systems worldwide.[115] Babar et al. (2020) point out that in the 
pharmacy profession, researchers consider there is a need to have better emphasis on 
professional competency, improved leadership skills and a move towards organizational 
change.[52] The health system in Qatar has excelled in the last decade; however, there is a need 
for additional medical workers in primary health care.[116]  
2.2.1 Future Access and Use of Medicines 
Antibiotic resistance could be managed by identifying thresholds for all antibiotics used in the 
country; therefore, an antibiotic policy to decrease the thresholds for each antibiotic and to 
control antibiotic resistance should be mandatory.[98] This study concluded that there are issues 
around belief systems and about the use of antibiotics for viral infections in Qatar. Also, the 
inappropriate use of antibiotics increases antimicrobial resistance, increased adverse medicines 
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reactions and extra cost. Another study suggests that community pharmacists can play a vital 
role in improving knowledge, views and antibiotics practices.[117]  
Diabetes is challenging Qatar's health care system due to its high burden. Therefore there is a 
need to reduce incidence by using surveillance and monitoring mechanisms.[118] Baines et al. 
(2018) argue that the pharmacy system should recognize advances in technology and develop 
the procedure and competencies to improve pharmacy dispensing and pharmaceutical care 
services.[119]  
Babar and Scahill (2020) explain that in the developed world, pharmacists work under a 
remunerated system, which does not depend on retail sales subsidizing professional activities. 
[120] However, in the developing world, there are challenges due to poor government regulation 
and utilizing less qualified staff rather than fully trained pharmacists. The use of generic 
medicines policies and their implementation are inconsistent among developed and developing 
countries. In those countries where there is a higher rate of generic medicines use, market 
structure supports healthy competition producing substantial savings; thus, considerable price 
variation exists between generic drugs and brand-name ones.[121] Therefore, extended 
community pharmacy services and use of generic medicines can improve aspects related to 
access and use of medicines in Qatar. 
2.2.2 Future Medicines and Pharmaceutical Policy Research  
In future medicines and pharmaceutical policy, researchers have suggested that the vital drivers 
are four main areas, including population demographics, technology, pharmacy as an institution 
of professionals and consumers of healthcare services, and new research skills developing from 
technological changes.[52] Eljilany et al. (2018) show that the number of economic evaluation 
studies is low, and this can be improved by the inclusion of health economics expertise to assist. 
Similarly, if the research focus is on the quality and quantity of health outcomes, 
pharmacoeconomic analysis and using the health economics expertise for making policies in the 
GCC countries can be helpful.[122]  
Nagaria et al. (2020) suggests that pharmacy practice research should investigate vital questions 
on the growing relationships among pharmacy, pharmaceutical and economic efficiency, 
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healthcare and public policy, which can be solved by managing barriers to change and developing 
a future model for pharmacy practice.[123] This model will help policymakers to make decisions 
on healthcare systems and therefore improve health outcomes.  
Babar et al. (2014) argue that future pharmacy practice research should include different 
researchers, such as sociologists, economists and epidemiologists, so the research is broadly 
acknowledged and received.[124] The future of healthcare needs a link among different 
professional practitioners to create a joint vision, and the same applies to medicines policy and 
research. Babar et al. (2018) also suggests that community pharmacy researchers should study 
community pharmacy practice issues about patient-centric services and pharmacy business 
challenges.[125] Bigdeli et al. (2018) commented that healthcare policymakers should participate 
in future collective decision making, which would give a chance to the policymakers to utilize 
extensive available information on medications, health policy and systems.[126] 
2.3 Summary of the Literature Review 
A medicines policy is a national framework that focuses on and explains the challenges associated 
with medicines access and use. In the last 10 years there are a number of studies covering overall 
health issues in Qatar however now there is an increasing focus on medicines and pharmacy. 
Medicines policy covers issues related to medicines marketing, access, distribution, pricing and 
reimbursement, formulary management, pharmacovigilance, and prescribing.  In Qatar, The 
Ministry of Public Health (MoPH) is responsible for many issues including medicines pricing and 
access. Very few original studies in Qatar are being conducted on pricing, access, and generics 
necessitating doing more work on the topic. The community pharmacy services include 
dispensing, however, there is a potential for advanced pharmacy services in the country. For this, 
pharmacists need advanced training and education. The challenges for pharmacists include 
patient counseling and remuneration. A number of studies conducted in Qatar's healthcare 
system also show the overall benefits of pharmacy services for patients and consumers. 
There were very few studies pertaining to medicines policy in Qatar. Though individual studies 
cover issues including pricing, antibiotics use, health promotion, and suboptimal use of 
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medicines, a study covering the overarching direction of policy was lacking. It is in this context 
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CHAPTER 3 
This chapter provides an overview of the methodology used in this study. It is crucial to select 
the right methodology for the research. The four philosophical areas in research ontology include 
epistemology, axiology, and logic of inquiry. Ontology is the study of the nature of reality and it 
describes a researcher’s views. Epistemology involves the knowledge of reality. Axiology looks 
into personal values. The logic of inquiry shows the research reasoning.[127] “There are also four 
paradigms involved including positivism, postpositivism (or realism), interpretivism (or 
constructivism) and pragmatism. These are relevant to pharmacy practice research.” Positivism 
and postpositivism are used in quantitative studies, interpretivism is used in qualitative studies 
and pragmatism is used in mixed methods research.[127]  
3 Research Methods and Qualitative Research  
Qualitative research is related to the interpretative perspective, whereas quantitative research 
informs about the empirical perspective. The qualitative research method is mostly used in 
pharmacy practice research to explore a topic.[128] The qualitative research method answers 
"why" questions. It also emphasizes in-depth study of people's words, actions, local situations, 
conditions, attitudes, values, opinions and stakeholders' needs. It can provide essential 
healthcare facts, reasons, opinions and personal experiences of participants.[128] Qualitative 
research methods include interviews, observation, document analysis and netnography.[70] 
While quantitative research is about numbers, qualitative research goes beyond numbers.[129] 
As quantitative research is built on “numbers”, the research methods will not be adequate to 
comprehend the feelings of individuals involved in a particular phenomenon.[130] On the other 
hand, qualitative research provides the opportunity to explore details and could enhance our 
understanding of medicines policy research.[131] It also answers questions about “why” and 
“how” various participants act in response to circumstances by revealing their beliefs and 
thoughts.[132, 133]  
Qualitative research can provide important understanding of health-related experiences by 
gaining insight into fundamental explanations, views and reasons from participants, providing 
precious details about the study objectives.[130] The phases in qualitative research include the 
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conceptual design and planning stage, empirical data-generation phase, analytical phase and 
dissemination.[72] The main techniques used in qualitative research are one-to-one interviews 
and focus group discussions. Supplementary methods consist of participant-observer research, 
action research, grounded theory, case studies and the Delphi method.[134]  The researcher 
should be certain that the carefully chosen design is suitable for the research’s main aim and 
objectives, as the validity of the illustrated conclusion in qualitative research is dependent on the 
chosen design.[135]  
In this qualitative study, a general inductive method was used and semi-structured exploratory 
interviews were conducted to carry out the research. The approach involved recorded interviews 
from stakeholders and transcriptions were done followed by thematic analysis. The interviews 
were designed to explore participants' opinions regarding priority medicines policy issues in 
Qatar. 
3.1 Why Qualitative Research was Chosen for this Study 
This study explored priority medicines policy issues for Qatar and identified the challenges and 
opportunities involved. The key healthcare stakeholders' opinions and perceptions needed to be 
gathered in the form of interviews to explore their views on medicines policy-related issues in 
Qatar's healthcare system. For this reason, the qualitative research method was the right 
approach to adopt.[128]  
The qualitative research method was used as it can provide an exploratory view related to study 
objectives and the topic. As there was no existent medicines policy in Qatar, hence this was 
considered the best method to unearth the details on knowledge, information, and 
understanding related to various dimensions of medicines policy. 
A general inductive method was adopted. A general inductive method is a systematic method for 
analysing qualitative data in which the analysis is directed by specific evaluation objectives.[136] 
Also, the general inductive method is comparative method of data analysis and so has been 
commonly used during qualitative research to generate results.[137]   
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3.2 Ethics Approval 
This study was approved by the University of Huddersfield Ethics Research Committee, Reference 
Number SAS-SREIC 14.5.19-2. Ethics approval was also obtained from Sidra Medicine, Qatar, 
Reference Number IRB-A-SIDRA 2019-0029, and ABHATH Research Center of Hamad Medical 
Corporation, Qatar. The ethics approval documents are available in Appendices 3, 4 and 5. 
3.3 Participants Selection 
The researcher contacted 55 stakeholders in Qatar by face-to-face meetup, email, WhatsApp and 
phone calls. The recruitment method involved meeting with key stakeholders and using a 
snowball sampling procedure. There were 21 participants selected for exploratory, semi-
structured individual interviews throughout Qatar using the selection criteria. The participants 
had been living in Qatar or the Middle East for more than five years. 
The inclusion criteria included: (a) participants working or involved in Qatar’s healthcare system; 
(b) participants having experience or working knowledge of medicine policy documents, different 
facets of medicines policy, use of medicines and access to medicines; and (c) participants well 
versed in the English language. The selection was intended to cover stakeholders from a broad 
range of healthcare and policy institutions in Qatar.  
The respondents were mainly from healthcare practices, pharmacists, and academia. All 
respondents have more than 5 years of working experience in Qatar as healthcare professionals, 
healthcare management, or in academia. They have the relevant background and knowledge to 
respond and answer queries on health policy and medicines use in Qatar. 
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4 0   
7 Consumer groups 3 0   
 Total stakeholders 55 21   
Table 2. Outline of the participants' areas of practice and profession.  
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3.4 Development of Semi-Structured Interview Guide 
The semi-structured interview guides were adapted from the study by Babar and Francis 
(2014).[67] Also, from the literature synthesis and informal meetings with the key stakeholders, 
changes, adaptations and amendments were made to this guide.  
In the interview guide, new questions were asked about the medicines policy in Qatar. The 
questions include “Where can someone find medicine policy in Qatar?” and “What are your views 
about the medicines policy issues and priority medicines in Qatar?” The interview guide also 
asked questions related to the process for marketing authorization of medicines. The specific 
questions also include the import/export of medicines. For example, “Are you aware of 
procedures to enhance support for the development or import of medicines that target an unmet 
medical need?” and, the question about “What kind of assessment does the newly developed or 
imported medicine go through before or at the time of application for marketing authorization.” 
There were specific questions about the future of overall health and medicine use in Qatar in the 
next 3 to 5 years. All these questions fit in with the overall aims and objectives of the study. The 
guide is available in Appendix 2. This was to cater for the Qatar healthcare system’s local needs.  
The amended guide was tested on 10 participants, and their views and perceptions were taken 
into account. The pilot interviews also provided the opportunity to estimate the time required 
for an interview. The logistics learned from the interview included (a) interviews should be 
conducted in a quiet area to avoid background noise; (b) it is necessary to maintain an interview 
bag or kit to keep all items and documents secure that are needed during the interview and for 
management of records; and (c) an Interview Guide check list was needed. This was to ensure 
that the ethics were followed. 
Amendments were also made as a result of the pilot interviews. The initial questions describing 
medicines policy, access and medicines policy issues were included. These questions were asked 
at the start to enable focus on more in-depth questions. It was explained that the study would 
be conducted from a healthcare system perspective. A new question about the use of medicines  
was also included before asking other questions. Two additional questions on future research 
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were also included. Some terminologies in the interview guide were further explained; for 
example, the term “marketing authorisation” (registration) was added. 
The final interview guide has four key themes as illustrated below: 
3.4.1 Priority Medicines Policy Issues 
 All participants were questioned about their understanding and definition of "medicines policy" 
and where to find documents pertaining to medicines policy in Qatar, and their views on 
medicines policy, procurement and the development of medicines policies nationally. Their views 
about how the State of Qatar or health institutions deal with priority medicines policy issues were 
also explored. 
3.4.2 Access to Medicines in Qatar 
Access to medicines is a vital component of medicine policy and crucial for the State of Qatar 
because of geopolitical issues and pharmaceutical imports from around the world. The questions 
revolved around perceptions about access to medicines in Qatar, and issues related to access for 
Qataris and expatriates. 
3.4.3 Use of Medicines in Qatar 
The use of medicines is another key component of medicine policy; therefore, this section in the 
questionnaire guide included questions exploring the participants’ understanding of the use of 
medicines, antibiotics used, compliance, concordance and prescribing guidelines, and as well as 
exploring these issues in the future.  
3.4.4 Future of Overall Health and Medicines Use in Qatar 
One of the objectives of this study was to find out participants' opinions on future issues which 
may impact Qatar over the coming years. The questions included participants' opinions on overall 
future of health, future issues related to access and use of medicines, and the challenges 
associated with these. There was also a section with an open-ended question for if they would 
like to add any further comments on the study.     
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3.5 Interviews 
3.5.1 Participant Recruitment 
A snowball sampling procedure was used to recruit participants. In snowball sampling, 
participants identify further participants.[138] The recruitment of the stakeholders was carried 
out by an email invitation, through follow up emails or calls, or through WhatsApp messages. 
When the stakeholders were contacted, an initial briefing was done on the research project for 
the introduction and seeking consent. If they showed interest and provided consent, then the 
invitation letter was sent by email. Fifty-five stakeholders were approached, of whom twenty-
four did not reply, three referred to their colleagues and two replied that they were not confident 
about participating in the research study. Twenty-one contacts agreed to participate. 
3.5.2 Conducting Interviews 
All interviews were done by face-to-face meeting, one-on-one with privacy, except for one 
interview which was held on Zoom Meetings because of the COVID-19 pandemic situation in 
Qatar. The interviews were conducted between September 2019 and March 2020. Before the 
interviews, an email was sent to all participants, which included an invitation letter and an 
interview guide. There was no financial compensation offered to participants. All interviews were 
conducted in the English Language. Each interview lasted for about 40 minutes. All participants 
have a full-time job and busy schedules; therefore, preference was given to participants' 
availability and, to reduce the participant engagement time for this project, the researcher drove 
to the participants’ locations in Doha, Qatar, to conduct the interviews. 
During the interviews, only the questions relevant to the study were asked. Formal consent was 
asked from the participants before starting the interview questions. All interviews started with a 
summary of the study, a meeting agenda, confidentiality statement and an inquiry whether the 
study participants needed to share any questions or concerns. 
All interview audio recordings were made on a SONY ICDPX470 Stereo Digital Voice Recorder and 
saved in the password-protected computer, and all files were named using a code number for 
further protection of confidential information. The Alpha numeric coding format was used and 
the details are shown in Table 2. 
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3.6  Data Analysis  
All interviews were transcribed verbatim. The coding was performed after reading the 
transcribed document, followed by the identification of themes and sub-themes for the thematic 
analysis. The analysis was performed by using the NVivo 12 software application.[67] The semi-
structured interviews provided spontaneous and natural conversation between participants and 
researcher.[132, 139] 
 The thematic analysis method is the most generally adopted method within qualitative 
research.[140] This method includes six steps. Clarke and Braun suggested thematic analysis is to 
be recursive rather than linear. In thematic analysis, the process may provoke the researcher to 
look back to previous steps if new data or newly emerging themes needs additional review. There 
are six steps that were followed for thematic analysis in this research.[140] (1) The data consists 
of interviews (2) The second step is to generate codes and the connections between data were 
explored (3) In the third step, the codes were examined and were subsequently organized to find 
possible themes. (4) The themes were reviewed by a two-step analytical process and a thematic 








This chapter provides details on the research findings.  
4.1  Demographics  
This study aimed to understand priority medicines policy issues for Qatar and to identify the 
related opportunities and challenges. For this research, we were invited 55 stakeholders from all 
healthcare sectors. Table 2 shows the participants' healthcare sector and the areas of practice. 
4.2 Themes 
The following themes appeared after the analysis of the transcriptions. The main outcome of the 
research include a series of themes and subthemes related to medicines access, medicines use 
and a series of exploratory priority medicines policy issues. These are all described below and 
they fit very well with the main aim of the research. The figure 1 is entitled as “ Themes and sub-
themes related to priority medicines policy issues for Qatar”.   
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Fig 1. Themes and sub-themes related to priority medicines policy issues for Qatar  
 
4.3 Priority Medicines Policy Issues for Qatar 
There were three subthemes around the understanding of medicines policy issues, current 
medicines policy issues, and medicines procurement.  
4.3.1 Understanding of Priority Medicines Policy Issues 
Our results showed that most participants have some form of understanding regarding medicines 
policy. 
4.3.1.1 Description of medicines policy 
There were different opinions regarding medicines policy among the participants. The drug 
supply supervisor described medicines the policy issue as:  
In general, so it starts by, I think, by procuring medication, how medication is procured, how the 
P a g e  40 | 106 
 
medication is prescribed, adverse events regarding medications, how to report these adverse 
events. That is it. (DSS1).  
However, an academic pharmacist described medicines policy as follows:  
I can describe 'medicine policy’. Medicine policy, in my opinion, are all regulations and guidelines 
on procurement, distribution cell and use of medications and other pharmaceuticals in a certain 
country; medicine policy has to be something that is written and documented guideline on how 
medicines are procured, how medicines are distributed, how they are used and how they are even 
disposed, within a certain country. (AP2) 
Whereas a physician explained a medicines policy as: 
 Medicine policy is the one that is governed by the state, which represents society and the whole 
purpose of those policies are to govern the safe use of medications for the general population but 
also to ensure that safety is balanced with the access around that and those are typically 
stipulated by the governing body for the country that is the jurisdiction where you live, and for 
this particular be…this would be the State of Qatar. (Phy3) 
One of the senior nurse managers of a hospital stated: 
I assume this is the use of medicines within State of Qatar to include national formulary. (SNM1)  
A pharmacy manager of a chain community pharmacy described medicines policy as:  
Medicine policy is the rules that regulate them, that flow of medicine from outside Qatar to the 
in user the patient, how that govern and control the process; what are the rules for access for 
medicines, for the prices and the availability and the expiry (in case of expiry) or…these the rules 
that govern medicine flow in Qatar. (PM1)  
Additionally, an academic pharmacist described the policy in the following words: 
I think it like a document written by experts, whether hospital level or national level or ministry 
level. It could include, it could start from like the basic level of developing the medicine, testing 
the medicine, approving the medicine and then basically approving the medicines for use, and 
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then we could have policies on procurement like how to get the medicine into a specific country, 
what requirements, what qualifications, what practices like the medicine, like what are the GMP 
practices; for example, for adopting or entering or procuring a specific medication to the country. 
(AP3) 
The following is the opinion of a registration and drug pricing manager in a public office on 
medicines policy: 
This is like big word medicine policy because it has different angles and different views. Here in 
the country, they are following the international standard for having the medications in the 
country, apart of that following GCC policies. GCC is one which is taken all the policies from WHO 
and international guideline for having a medicine in the country. (RDPM1)  
A physician in a hospital described medicines policy in the following words: 
 My understanding of 'medicine policy' is that it is a set of regulations which governs the provision 
of medicine at different levels, including the community level, in the hospitals and to the patients 
at various healthcare facilities. (Phy4) 
4.3.1.2 Availability of a national medicines policy in Qatar 
Here is the statement of a registration and drug pricing manager related to medicines policy in 
Qatar: 
We do not have like such one bundle of documents, which is called medicine policy but to have it 
in different documents. Yeah, but it is not like a one booklet, which is known as medicine policy to 
be available in one document. (RDPM1) 
A drug supply manager believed that medicines policy and all policies were available on the MoPH 
portal; he stated: 
In the ministry of public health portal, all the policies related to…starting from the license of 
pharmacy professionals up to the level of registration of a new medication, we will find the rest 
of medicines registered. We find what are the restrictions, anything related to the policy of usage 
or access to medicines in Qatar. We will find it in the portal, very transparent. (DSM1) 
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On the other hand, other participants believed that the medicines policy was not available. Here 
is the opinion of an academic pharmacist on Qatar's medicine policy:  
The State of Qatar does not have any written medicine policy. This is to the best of my knowledge. 
There is lack of national medicine policy in the State of Qatar, but in place, of course, there are 
some unwritten regulations and rules related to access to medicine. So issues to access, 
availability, affordability, there are some written documents, even with the pharmacy and drug 
control, but there is no consolidated national medicine policy that covers all this aspect as well as 
aspects related to generic medicines, which are also part and parcel on national medicine policy. 
(AP2)  
The drug supply supervisor’s views about the availability of a medicines policy in Qatar were as 
follows:  
Well, if there is a published national medicine policy, I don't know. I am not sure, but I know that 
there are some regulations for importing medication in Qatar and based on this, we submit for 
import permit approvals unless the item is registered other than that registered medications. But 
about a policy or a national policy I did not, I have not seen. (DSS1)  
One of the physicians referred to the MoPH website, and he outlined this in the following 
statement: 
In order to get information for medicine policy in Qatar I think the best source for it is the QCHP 
documents and they are available online to the general public as well as to the healthcare 
providers. (Phy4) 
4.3.2 Current Medicines Policy Issues 
The participants had differing opinions on medicines policy issues. However, the two most 
common issues were where to find the policy, as well as issues regarding medicines registration 
processes in Qatar. 
4.3.2.1 Issues in finding and following the medicines policy  
Most participants felt it was a challenge to find, understand and follow the medicines policy in 
Qatar. A pharmacy manager replied about the medicines policy in the following manner: 
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I think there is no strict policy for medicine in Qatar. So, maybe this makes it like not much clear 
for every health care provider; you know, there are some issues that I am not clear, maybe 
regarding some of the rules for some medicines. Just some issues, prescribing issues, I am not sure 
about; not everything is clear, maybe this is because it is not stated. Because I think reason for 
that, it is not created. There is no medicine policy clear for everyone. (PM1)  
Also, a drug supply manager said about the medicine policy in Qatar:  
It would be better to have one policy that covers everything. (DSM1) 
Additionally, a hospital pharmacist said it was a challenge to find policies on modern healthcare 
technology to reflect and guide current healthcare practice:  
My views on the policy itself, I think It's quite dated, and also there are some aspects of it that 
need modernizing, particularly now that we are dealing a lot more with electronic prescribing, 
with automated dispensing tablets. Things have moved on so we no longer keep in paperwork for 
many, many things and I think the medicines policy should take time to reflect and review what 
change is necessary, and where the country that is full of ex-pats, it is important that the 
document is translated in English. A lot of the time, it is in Arabic and Arabic only, so finding a 
reliable translation is quite difficult. (P1) 
An academic pharmacist emphasized the importance of the medicines policy, and regulators 
were aware that there is a need for a written national medicines policy:   
Priority medicine policy issues are very, extremely, incredibly important and definitely this comes 
as part of medicine policy in the country under the umbrella of national medicine policy. 
Unfortunately, we do not have the national medicine policy, that does not mean in the State of 
Qatar. We do not have issues from the regulatory authorities and other healthcare institutions 
related to the priority medicines. I think the policymakers are fully aware about the priority 
medicine issues, but a written policy because of the lack of national medicine policy. So also, there 
is no any kind of priority medicine policy that is written. (AP2)  
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A physician shared a different view and pointed out that Qatar is a multicultural society. There 
are challenges in communication and understanding of medicines policy.  
Like every healthcare setting throughout the world, there are some issues, and especially in Qatar, 
we can see that the…my personal understanding is that it's a multicultural society. So overall 
awareness of the public is a major issue, especially people coming from abroad or especially 
people coming from third world. They have a poor understanding of the 'medicine policy’, and 
that is in my understanding is that this is one of the major issues to be addressed. (Phy4) 
The pharmaceutical distributor pointed out that medicines policies should be self-explanatory, 
and the regulator should help healthcare providers and stakeholders to understand the 
medicines policy. The pharmaceutical distributor stated this in the following manner: 
Priority medicine policy issues, actually, there are many discussions. Everywhere there is people 
speaking about policy, medicine policy, medicine rule, how to deal with policy, how to deal with 
medicine, but I think it still needs a lot of efforts. It needs a lot of, to teach people or to read to 
make the message more simpler for the healthcare provider, so as they can digest the word 
'priority medicine' and they can put it as part of their daily activism with whatever, whether it is 
service or it's medicine. I mean to provide the medicine or manufacture the medicine or distribute 
or dispense the medicine. (PD1) 
4.3.2.2  Medicines registration for Qatar 
Every participant had an opinion about a different aspect of Qatar's medicines registration, and 
there are a few quoted here. There was a general concern that medicines registration takes a 
long time, an average of nine months. However, there is a fast track registration process for some 
medicines, which may take four to six months by the MoPH.  
The participants (DSS1 and PM1) reported that registration of medicines takes a long time, which 
resulted in the reduced availability of medicines. This is also being identified by participants (DSS1 
and PM1) and this fits very well within the main theme regarding access to medicines.  
Here is the opinion of a drug supply supervisor about the medicines registration process in Qatar:  
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Well, frankly speaking, when we talk about Qatar and the MOPH and the drug control, there are 
no…I cannot find like a written policy, or there is a scheme for registration if we want to talk 
regulatory from the regulatory aspect. There is a scheme for the regulatory requirements for 
registration of all this, but for the policy, no. Nowadays, they are really accelerating the process 
because of all that is happening here. So before it used to take at least nine months but nowadays, 
maybe more than four to six months. (DSS1).  
Also, the pharmacy manager stated, regarding the time consumed with regards to medicines 
registration in Qatar: 
Registration for the medicines is taking a long time. They have some…there is something called 
fast track for some medications to be fast track registration. So registration usually take a long 
time, but they have some fast track medication registration in the Ministry of health. As I know, 
there are some examples of medicines, especially after the embargo, there are some medicines 
that quickly enter to the Qatar, and they have some temporary solution like they will make 
temporary parallel important approval. They will not give the approval for certain distributors 
here to make medicines available until they finish the registration process. They have some 
solutions here. (PM1) 
The hospital pharmacist at Hamad Medical Corporation (HMC) explained the process for different 
medicines registration processes for approval, direct purchasing and bringing medicines to HMC 
for all patients. The following was stated by the hospital pharmacist: 
See, we have our own process in HMC. Usually, what we do is the ones which are prioritized, 
essential, which sometimes, which is lifesaving at times, so, we have very accelerated process. So 
that is been there because we have our own process in HMC, where we directly contacted the 
authorities in other countries and embassies, and they would contact the manufacturers, and it 
comes through the embassy when it is urgently needed. So, there is a process in place until unless 
the product is not available. (P2)  
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All other healthcare sectors must get approval from MoPH for any medicines, including private 
sector pharmacies, distributors, hospitals, clinics, national and international manufacturers, and 
suppliers. The following is a statement by a pharmacist from the hospital: 
They go through the Ministry of Public Health, request with does not go through HMC as such. So 
use of health, you look into all the certificates’ quality, etc., etc., see if all the requirements are 
fulfilled even if FDA product is introduced here. It's easier than uploading, which is not FDA 
approved or EMEA approved, but that goes at the Ministry of Public Health level. (P3) 
4.3.3 Procurement of Medicines and Medicines Supply Chain  
Two points were noted within this subtheme, one was on the import of medicines, and the other 
was the manufacturing of medicines in Qatar.  
4.3.3.1 Import of medicines 
For the import of medicines in Qatar, the registration application must be submitted to MoPH. If 
the FDA, Health Canada and EMEA have approved the medicines, then only MoPH will review the 
application for medicines registration. A pharmacist in the hospital explained this in the following 
manner: 
They go through the Ministry of Public Health, request with does not go through HMC as such. So 
use of health you look into all the certificates’ quality, etc., etc., see if all the requirements are 
fulfilled, even if the FDA product is introduced here. It's easier than uploading which is not FDA 
approved or EMEA approved, but that goes at the Ministry of Health level. (P3)  
Also, the drug supply manager described the import of medicines in the following manner: 
Ok, what I am aware about is that certificate of origin, certificate of analysis, certificate of 
materials kind of like the same files that are submitted to the FDA with all the research database 
that have to approve. One mandatory thing [is] that you cannot register in Qatar unless you are 
just registered either in FDA or EMA. So that is mandatory that you cannot start by Qatar. (DSM1) 
The drug supply supervisor added that the MoPH has a special import process for some 
medicines:  
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Well, sometimes they provide like a special import for this medication, until it is registered. They 
usually do so. If the medication is needed and still some documentation is still missing, they 
provide a special import approval based on, of course, the need and the justification. (DSS1) 
4.3.3.2 Manufacturing of medicines in Qatar 
There are a few national pharmaceutical manufacturing companies in Qatar. After the embargo 
placed on Qatar by other GCC countries in 2017, some pharmaceutical manufacturing started in 
the country. The following was explained by a drug supply manager regarding the local 
manufacture of medicines in Qatar: 
Yes, local manufacturing has started before the embargo, mainly Qatar Pharma. They were 
producing only intravenous fluids but now, after the embargo, in Qatar feels that the availability 
of medication is part of the national security. We have now kind of like four-five factories inside 
the country. They focus on the essential medicines. Still country is importing most of the 
medications from outside, especially the new medicines and the generic medication. (DSM1) 
He also stated the following on contract manufacturing: 
One of the things that they are to secure is to kind of like buy the shares of the main 
manufacturers. So if I can't manufacture internally, I will secure the essential medications on the 
supply chain through buying shares in Byer, Pfizer, so nobody can stop the supply to the country. 
So that's what I am aware about. (DSM1) 
4.4 Access to Medicines in Qatar 
4.4.1 Process for High-Cost Medicines for Qataris and Expatriates 
All medicines are paid for by MoPH in all public sector hospitals and primary care clinics. This 
payment is in full for Qatari nationals and up to 80% for non-Qatari residents. The 20% medicines 
cost for residents is paid by either employer insurance or private insurance, including for high-
cost medicines. In the private sector, all medicines cost is paid by MoPH for Qatari nationals, but 
all residents have to pay the full cost of medicines. Here is what an academic pharmacist had to 
say about access to medicines in Qatar: 
Well, as far as I know, there is no differentiation. If an expat needs like an expensive chemotherapy 
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medicine, they are not denied access to it. So, if that particular drug is needed and it's in stock 
and available in this country, the patient will receive it, and you know this is the big benefit about 
living in this country is that the Expats are not denied medical care. (AP1)  
The following is a statement from a registration and drug pricing manager about the cost of 
medicines:  
For Qatari, no problem as they are not paying. But the good thing also for the expats. Government 
always paying 80% of the bill. They only pay the 20% and even for the chronic diseases such as 
cancer and diabetic patients and cardiac patients, paying only 10%. (RDPM1)  
Additionally, a pharmacist in the hospital stated the following on high-cost medicines:  
So our organization, there is a high-cost committee, so that reports to the pharmacy and 
therapeutics committee. They provide some conceptual structure around a high-cost medicines 
and some clinical governance on when and how they should be used. So we do have some, you 
don't have to be national. Whether it is national or the expat in terms of the patients, there is no 
beyond distinction between the two. Some of the organizations do. We don't. (P1) 
For Qatar's residents, the high-cost medicine prices or co-payment can also be financially 
managed by their insurance and/or other societies in Qatar. Here is what the pharmacist at the 
public hospital stated about the insurance:  
The insurance has not been there, so I would emphasize insurance. The country looked at the 
insurance before, and they're still working on the insurance now. So once the insurance comes, 
then probably it should not be a problem with a higher cost, even at this point. It's not a problem 
at all. But for private sectors, there are many issuance companies which is covering that cost, but 
in HMC, the price is not a problem. (P2)  
Also, the pharmacist of a public hospital explained the availability of a medicines support system:  
There are impressive support systems available. So there are societies as such like for expensive 
medication. Multiple sclerosis society, they will recruit funds and support addition. Red Crescent 
is a very big source of funding as well. There are all kinds of charity organizations which will help 
the patients who need the financial help, also for the expensive medications as such, yeah. (P2) 
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4.4.2 Current Issues about Access to Medicines 
Transportation from the manufacturing country to Qatar is a concern because sometimes this 
could delay the medicines. The manager of registration and drug pricing stated this as follows: 
We are trying to encourage local manufacturing plants to manufacture this kind of product 
locally. Because other issue is waiting for the transportation issue, you know, have the medication 
timely. It takes time. Yeah, it takes time. Sometimes you are not receiving at the time we need. 
(RDPM1)  
Also, the senior nurse manager talked about medication supply issues: 
We have good and easy access for the drugs that are available in the country. You know, again, I 
know that limits are what the prescribers can offer to some patients based on, you know, what is 
available in-country and this goes down even both to the type of the drugs and the formulation. 
So I know those are the same challenges, and we don’t have a consistent access to drugs supply. 
(SNM1)  
Additionally, a physician in the hospital stated the following regarding availability:  
One thing I noticed over the last couple of years of working here in Qatar is that range of medicine 
availability, range of medicine is an issue. Again, there is a limited range of available medicine in 
some areas, so that is…and especially the narcotic, analgesic and their prescription of the patient 
and availability of patient for taking home is an issue. (Phy4) 
The pharmacist in acute care highlighted issues including access to medicines without a 
prescription, repeat supplies of narcotic medicines and holding medicines in stock, as availability 
is uncertain. 
 A lot of things are built, or they are made for sale without a prescription, which means that people 
can access them but we are not sure if they are using them properly. Because you can just buy it 
without a much control. (P1)  
Other access issues are narcotics and psychotropics because of the prescription length. That can 
cause a bit of a problem because patients have to return to the pharmacies quite often to pick up 
the medications. Yeah, it's a five day supply. So as per the policy, it is a limited number of days. 
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Also, medications that need more than that you have to return again. So it's quite strict laws on 
narcotics mainly but also on psychotropics. (P1)  
The availability of medicines was also discussed by the acute care pharmacist: 
The other access issue could be whether to stock or not because we are relying heavily on imports 
we all been holding within a country so, you know, it's not something that's available now. That 
can cause an access issue. (P1) 
Qatar’s pharmaceutical market size may also affect medicines availability, as a drug supply 
supervisor in a hospital explained:  
The issues are mainly by being a small market. Not all registered medications are available. The 
high cost, let me say the essential medications, most of them, they are not registered and the 
companies, they are not keen to register because it's easy to put a…to have it here available in 
the market through Hammad. They [MoPH] are trying to like formalize a unified national 
formulary for all Qatar and to…and to just to force all companies to register their medications to 
be able to have like a fair like availability for a medication. (DSS1) 
The availability of a national medicines policy, private medical insurance coverage, and the use 
of generic medicines were also some of the issues described by an academic pharmacist: 
The issues surrounding around access to medicine…the issue of the national medicine policy, 
because when there is national medicine policy, national medicine policy was clearly state all that 
is needed in terms of giving access to the medicine and so on, and when it does not exist, it creates 
a kind of disparities or differences or inconsistencies in terms of how different organizations 
operate in terms of giving access to the medicine. (AP2)  
There is differentiation, and that is linked to when they are employed, the employees, the level of 
health insurance that they are given. It's not the same. So there are issues of safety there. There 
has to be some kind of creating safety name for the disadvantaged population. I think this is an 
issue in terms of, not completely they do not have access, but it is the restricted kind of access and 
if there is a policy in place as well as users’ organizations that are employing them, will improve 
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the insurance coverage. That will bring the uniformity in terms of how people are getting access 
to medicines in the State of Qatar. (AP2)  
They are barriers in terms of access to medicines, and those who will understand when you talk 
about most of the institution, there is kind of misconception, for example, about the use of generic 
medicines. So because of these misconceptions, the clinicians don't trust, and the patients also 
they don't trust if you give them anything. This is a huge expenditure on health and therefore, 
there are…there could be also barriers from that perspective. (AP2) 
On the other hand, access to medicines without prescription emphasizes the pharmacist’s role 
at community pharmacies. This should be to educate and optimize medicines use. The following 
was stated by the academic pharmacist. 
We have too much access actually, and with that in any one of the public can now go to the 
pharmacy and buy antihypertensive that you know, without any prescription. So we have too 
much access that has to be restricted honestly on some drugs, yes. (AP3) 
 The pharmacist is not really offering a good advice to the patient. Since the majority of the 
medications are available over the counter, pharmacist should have a role in that more in 
educating the public about the optimal use of medications. (AP3) 
4.4.3 Need for Further Research  
The following section elaborates thoughts on areas for future research. For example, a pharmacy 
manager at the community pharmacy stated that research is needed on leftover medicines at 
patients' homes:  
Yeah, probably, what people do with the incomplete medications or unused medicines. One of my 
concerns. I would love to have a research done on that so that there is no left-over medicines at 
home which can harm another person. (PM2) 
A registration and drug pricing manager stated that there is a need to develop a comprehensive 
national medicines policy: 
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Like further research and to compile these [medicines policy] documents in one document 
together… Because most of the practitioners are coming from abroad expect the same thing from 
the home country but this country is very unique for the medicine access. (RDPM1)  
This view was echoed by a hospital pharmacist: 
I would be interested to know about over the counter sales and the clinical effectiveness of doing 
that, so where you are frequently selling products without having much guidance from the 
physician or the prescriber and then a pharmacist too. What is the impact of that and how does 
it compare to some of the standards around the world? (P1)  
Academic physicians have an interest in developing policy, regulation and improved patient 
safety: 
But clinical choice is a big problem that is not…now we established whole clause of medical 
education, and it has no access to clinical choice because the legal aspects are not clarified. So, 
no drug companies, they have to start; no doctors, they have to start; because there is no 
justification and there is no monitoring if side effects that may identified. There is no unit to say 
"No, no" this is now to stop, and also, the legal implications of making mistakes in relation to 
research are too tough. You can go to jail if you make a mistake, and they are working on that. 
(AcPhy1)  
More research is needed on clinical practice guidelines, as a physician in a public hospital 
suggested:  
Actually, the most research I think should be, for each problem, or medical problem, should be 
matched it by guidelines; and because it's still doubt, the practice at the level of institute. It's not, 
again, with the policies or guidelines. That means it is very open to each physician to use whatever 
he thinks is best for the patient unless this utilize or done. (Phy2) 
Antibiotic resistance is another area where physicians would like to see some work:  
I think the issue of resistance of different organisms to antibiotics and people come from a 
different part of the world. They already have access to the even very high potency antibiotic, 
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which they take inappropriately, and they come here with different set of resistance of 
microorganisms. While at the same time, the good majority of the people, who come from a part 
of the world where there is very controlled access to these antibiotics, and they have a different 
actually resistant status. This area needs a bit more exploration, attention or work need to be 
done. (Phy4) 
 It was also suggested by a physician that a sociological study about patients’ expectations on 
medicines is needed: 
 I think it will be an intriguing sociologic study to understand why every patient that walks in wants 
to talk over the medication. If I don't give a medication, I am considered a bad doctor, and it will 
be an interesting to understand the why of the population because it puts an automatic conflict 
and the distrust in the system if you don't get a medication. And one of the reasons why antibiotic 
overuse here is because they just won't go away without any and think you are a bad doctor and 
all those things. (Phy3)  
Similarly, pharmaceutical distributors would also like to see more research on antibiotic policies 
and guidelines:  
If I think about the research, I will think about the type of antibiotics available in the country. I 
think it need to be looked in term of suitability of this medicine to the situations in Qatar, whether 
it is really effective, or it needs to be. I mean antibiotic policy. (PD1) 
An academic pharmacist also emphasized the need to do research on medicines availability, 
affordability and cost: 
So like I describe, that depth of literature or the scarcity of literature, inability to issues of medicine 
accessibility, availability, affordability and cost. I think this is a niche area of research; wherever 
there is a need of researchers that are working in the area over a medicine policy to do more in 
terms of understanding these issues. (AP2)  
Similarly, a hospital pharmacist also talked about research on generic medicines and the barriers 
related to the use of these medicines: 
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The first thing is I will talk about generics and brands, so that will be the best thing to look at in 
which people have looked at it before, but there are some barriers which need to be overcome 
initially. (P2) 
4.5 Use of Medicines for Qatar 
As shown earlier in Table 3, four sub-themes were observed within this theme. These include 
“general description on the use of medicines”, “present issues with regards to use of medicines”, 
“challenges and opportunities with regards to use of medicines”, and “future research on the 
topic”. 
4.5.1 Use of Medicines 
There were differences of opinion regarding the use of medicines. One physician reported as 
follows:  
Use of medicine is in Qatar is similar or same as every anywhere else where modern healthcare 
facilities available that over the counter medicine available to the people. (Phy4)  
A drug supply supervisor described the use of medicines in the following manner: 
Use of medicines is mainly medication prescribed by the physician for a specific indication. This 
indication has to be mentioned in the…mainly from the regulatory perspective the…in the insert 
leaflet, or it has to be registered for this indication. (DSS1)  
An academic pharmacist made an interesting point:  
This seems to be a very broad question, and I don't know where to start, in fact. So, the use of 
medicine from the perspective of utilization, from the perspective of healthcare institutions or 
from the perspective of regulatory authority or from the consumer perspective; I think if you talk 
about use of medicine, you should look at it in different perspective. (AP2)  
An academic pharmacist described this from a patient’s point of view: 
If I will say from the patient’s perspective, it's how the patient is using the, basically, the 
medication, so proper or not proper according to the direction or not direction. Is it the right drug 
dose, not a right dose, for there is good duration or not a good duration? Yes. (AP3) 
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The hospital pharmacist explained the use of medicines in the following manner.  
For HMC, we have JCI accredited. We have something called a chapter medication use…utilization 
medication advisor that clearly tells us how things have to run around, right from the start if you 
talk about how do you select a medication; how it goes into the P&T committee, then how it is 
approved, then how it has to be dispensed, how it has to be prescribed, how it has to be stored, 
then how it has to be monitored. (P2) 
4.5.2 Present Issues Related to the Use of Medicines 
The study participants stated concerns about a number of issues related to patients using 
medicines; these also include prescriber issues and broader medicines policy issues. An academic 
pharmacist emphasized the need to educate patients regarding the appropriate use of 
medicines: 
Well, I think the biggest thing has to be that the general public has to know more about how they 
should be using the medicines properly. They get the prescription, they don't get much of the 
information from doctor, and they go to the pharmacist at the pharmacy, and the pharmacist 
tells a bit of an information, but still, they don’t know much that much, and that leads to a big 
problem. (AP1)  
The registration and drug pricing manager at MoPH described this in the following manner:  
We realized that patients are misusing this medication. For this, we added it to one of the 
controlled drugs, which is done once in a month only in order to avoid this kind of misuse. (RDPM1)  
Because medicines are free or subsidized, patients have more medicines, which increases misuse 
and harmful effects of the medicines. He explained that. 
Issue is that the medicines, although is coming from abroad very expensive, and registry is free 
and being dispensed to patients, some of them are free and some are highly subsidized. This 
affects the use of medication. (RDPM1)  
Another participant, a drug supply supervisor reported: 
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For me also is the adverse event reporting system for me. It is…it is…we lack this here in Qatar. 
(DSS1) 
A physician mentioned the issue of expired medicines at patients’ homes: 
The only thing is that a lot of people might have a…might have lots of medication which have not 
used, maybe hanging in somewhere in the house. So maybe from time to time, there would be 
like a collection of this expired medication and…and the medication which are not used, so they 
can be disposed. (Phy5) 
A few participants stated their concerns regarding medicines use policy issues; for example, a 
pharmacist stated: 
So I don't know about any medication-related national policy being available on Qatar. The only 
thing is I know is that they have the programme for the vaccines that Ministry of Health is 
executing and monitoring. The only advice that I would have is that the policy [should be] 
nationwide. It's good to have one nationwide that covers all the stages of medication 
management and how the institutions have to follow that. (P5)  
An academic pharmacist stated the following regarding a specific policy for the use of medicines: 
I think when we have national medicine policy, it is a big umbrella that encompasses all these 
issues, including the issue of use and supply and procurement of medicine. It talks about medicine 
misuse and abuse and regulations that are governing all of this, and when there is lack of one, we 
will continue to record the issues related to all these branches that come under the big umbrella. 
(AP2)  
A pharmacist from a public hospital talked about the medicines policy and use of medicines in 
the following manner: 
I think we need to have like a more standard medication policy or more public awareness about 
the optimal use of medications and this, because now…initially it was like Hammad corporation, 
now another corporation like Primary Healthcare, Sidra, the Army, all of them. They have like now 
hospitals, polyclinics and standard policy will be beneficial. (P4) 
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Antibiotic prescribing and the prescribing policy were also discussed by a few participants. An 
academic physician explained this in the following manner: 
As I say, the restrictions and training of the staff not to prescribe antibiotics as widely as it is done, 
this is the major issue, and I think this is deep major as many others are not like that. (AcPhy1)  
A physician in a public hospital stated the following on prescribing and the use of antibiotics, as 
well as narcotics: 
What to my understand mainly is now currently towards the antibiotics and towards a narcotic; 
others general clear policies is not there actually. And even for the narcotics, as I mentions, it 
solves now only ICU doctors and anaesthesia and neurology only were supposed to write such a 
medicine. (Phy2)  
A pharmaceutical distributor opined that different stakeholders need to adhere to regulations to 
achieve optimal use of medicines: 
I think the main issue [is] that we need to teach the people that the adherence to the regulations. 
It doesn't mean we don't want to give you the drug. We want to choose that when you use the 
drug. It should be used in the right way, and it should achieve the target of using the drug. (PD1) 
4.5.3 Challenges and Opportunities Regarding the Use of Medicines 
The participants suggested that a computerized patient’s health record system for all healthcare 
providers would resolve prescribing and medication management issues. The pharmacy manager 
in community pharmacy indicated that: 
There are no patients file and this will lead to misuse for a patient medication. (PM1)  
A pharmacist would like to have a national health record database system in place: 
A unified health record system, national health record system for the whole country, should be 
implemented in this country, so that every health care provider knows what medications are being 
used by each one. (P1)  
Healthcare providers face challenges including patient education and awareness. This is the view 
of a physician working in a private hospital: 
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Challenges for the physicians are that they face because they have to restrict the excessive 
medication usage. In this regard, physicians face challenges. So it just needs some sort of 
education and proper continuous education, public awareness. (Phy1)  
A pharmacy manager suggested that there is a need to educate society on the proper use of 
medicines: 
Probably the need to educate more the society about the importance of the right usage of 
medication and honest medical fraternity, physicians, pharmacists to ensure that this education 
reaches the society. Probably there can be outreach methods, joining the universities and the 
community pharmacies, community medical facilities, where the patient medical personal 
interaction is more. (PM2) 
Additionally, an academic pharmacist emphasized that public education is needed with regards 
to the role of pharmacist in the healthcare system: 
 So that the public understands that the pharmacist is not like a business dealer, but the pharmacy 
there is for education and actually doing medical treatment with the drugs when they go to see 
the pharmacist. (AP1)  
An academic pharmacist also emphasized the role of the pharmacist and public perception: 
I think the main challenge is basically is about the role of pharmacists. You know, the public here 
is not really aware of, or they don't really expect the pharmacist to give them good education 
about optimal use of medication. So you may find some patients not really accepting the idea of 
having a pharmacist counselling. They only look at the pharmacist who dispense the medicine. 
(AP3) 
A few participants also mentioned about the challenges of not having national antibiotic 
guidelines for Qatar's private and public sectors. The drug supply supervisor from a hospital 
pointed this out in the following manner: 
So the challenges are the issues in the system. The opportunities that you have here is to create 
our national guidelines. Hammad (HMC) has the guidelines. Sidra (Sidra Medicine) has guidelines. 
Some of our private hospitals which are in the primary stage, but we need national guidelines. If 
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you need national health insurance and national health codes, why not to have national 
guidelines also? (DSS1)  
A senior nurse manager commented on the issue of guidelines as follows: 
 I think publicizing the guidelines better around these antibiotics, and holding the institutions 
accountable of antibiotics use, and meeting those recommendations and guidelines…it is a big 
opportunity that we can do fairly compact country to kind of hold providers accountable to the 
published guidelines. (SNM1) 
The senior nurse manager also stated the need to have a robust primary care model in the 
country: 
You know the primary care model is still building in this country, and I can go to seven different 
places and I get the same medication for my child from seven different people. You know, without 
a clear good primary healthcare model that was…I could take inside the system and outside of 
the system, and without that constant kind of reminder of the primary care model we can 
overprescribe and get into some pretty dangerous situations. (SNM1) 
A drug supply supervisor in a hospital pointed out the lack of a pharmacovigilance system in 
Qatar: 
Well, Qatar lacks pharmacovigilance system, and if pharmacovigilance system is available, 
everything regarding medicine will be documented. Specifying the indications, following up on 
adverse events, adverse event reporting, I think this is mainly what is missing. (DSS1) 
An academic pharmacist also mentioned the need to focus on quality use of medicines: 
I see an opportunity for the academia to take the lead in terms of more research related to 
medicine use and quality use of medicine, whereby you can have a centre for quality use of 
medicine that decides the whole area and produce more information on how you can advance in 
your country in terms of medicine use and supply in the country. And that comes back to also 
medicine safety issues in a country. (AP2)  
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4.5.4 Future Research on the Use of Medicines 
A number of participants suggested more research should be done on various issues. An 
academic pharmacist stated this in the following manner: 
They should do more research on what are the barriers that are preventing the advancement of 
pharmacy practice in community pharmacies. What is it that causing the barriers, and how those 
barriers can be overcome, because this is got to be one of the biggest areas where it can be 
improved in community pharmacy practice. (AP1)  
Another hospital pharmacist also stated the need to research areas such as patient counselling 
and the use of medicines: 
I would like to understand better on what the information is given to the patients on the use and 
how is that information is given in quality of that; so we talked little about the things like labelling 
and counselling and advice, like how do we capture some data or not to understand how about 
the work and what can be done differently. (P1) 
Some participants suggested topics such as narcotics and control of medicines, supply and 
procurement issues. The following was suggested by a physician. 
Prescription medicine for patient to take home and some of the strong analgesic medicine and 
antipsychotic medicine, which patients definitely need, and system here puts a little bit restriction 
of these medicines like in terms of provision to the patient. I think this area need an immediate 
and urgent and very focused attention. So availability are of these medicine to the patient from 
the institution or at the community pharmacy level is very limited. (Phy4)  
An academic pharmacist also emphasized the need to look at supply, demand and consumer 
satisfaction issues: 
The regulatory agencies are looking at policy-related issues, looking at supply and demand and 
procurement related issues from different aspects. And as well as I think it is important also to 
look at the patients and consumer satisfaction in terms of use of medicine, in terms of how the 
system operates. (AP2)  
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A hospital pharmacist also suggested the need for research on pharmacoeconomics and on drug 
use evaluation: 
The first thing would be the drug use evaluation. So you need to evaluate how well the drug is 
working; a lot of pharmacoeconomics research that can be done and we are doing a couple of 
researchers in for pharmacoeconomics, which is been booming now, and we are really there 
looking at the cost [and] how effective the medication is. (P2)  
An academic pharmacist suggested research should be done on disposal of medicines by 
patients: 
Like there is no really clear system on how to dispose medications. That is, just many people are 
just throwing it in the garbage or in the toilet. (AP3) 
4.6 Future Overall Health and Use of Medicines for Qatar 
There were three sub-themes within this theme (see Table 3): overall health issues in the next 
three to five years, future access and use of medicines, and research ideas for the future. 
4.6.1 Overall Health Issues in the Next Three to Five Years 
Most participants were of the view that overall health in the next three to five years will be better 
because Qatar has started Qatar National Vision 2030 and National Health Strategy 2018-2022, 
and the focus is on better health outcomes.  A pharmacy manager explained this in the following 
manner: 
With the new standards of education or new standards of practice which is being envisioned by 
the Qatar by the vision for every five year, there is going to be a definite change which will actually 
reflect upon better health practice, better health outcome and better health reports in very next 
three to four years. I am very hopeful. (PM2)  
The senior nurse manager was also hopeful about future overall health and investment in the 
primary healthcare model: 
It is such a great health care system. Its number five in the world so it doesn’t…there are so many 
opportunities and they have done just massive investment in it, and I think that the primary care 
model is just really is good, but just making sure it gets embedded and not the kind when people 
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get into the system, they stay into the system and they don't jump providers to go to private 
physicians; because that's really what's gonna make this country fantastic, that investment in the 
primary health care model. (SNM1)  
A hospital pharmacist mentioned this in the following manner: 
The overall health, I think, with the current direction of Qatar, one aspect is that I hope they will 
continue with promoting sports and physical exercise and preventive measures to prevent 
diseases and so on, and you can see a very good progress in this. (P5)  
An academic physician expressed optimism on the future of overall health: 
I think it's a very good public health strategy they have made, and it's very operational and to the 
point, and I have seen that they have made cancer solidarity and they have made the heart 
hospital. When you are focused on things like now, they want a focused public health strategy. 
They take things, and they implement, so I think it will improve. I am quite optimistic. (AcPhy1)  
The following was stated by the drug supply supervisor on the future of overall health: 
Well, although all these issues and obstacles, but I see that it is promising because I lived in the 
different GCC countries and I experienced here the best health systems, really, for I am talking 
about me and my kids and everyone. Their main concern is health, either you are a Qatari or an 
expatriate. So from…I lived in three other countries in the GCC and I can tell you for sure that this 
is my best experience. (DSS1) 
The drug supply manager also emphasized the need for having national health insurance in the 
future:  
So I see, once the national insurance is already launched, more and more investors will come and 
invest in healthcare market in Qatar. We will find decent polyclinics and private hospitals, and 
that's how I see the market, and that's based on the fact that it started already when they piloted 
the programme for a while, and it will recap again once restarted. (DSM1)  
A physician linked the future of overall health with obesity and life style: 
I think that in Qatar, maybe like in everywhere else, we heading to more obesity and less…and 
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more proper diseases which are related to obesity. However, from what I see, the health 
organization of the government is trying to encourage people to…for healthy diet, for active 
treatment, for having a lot of voluntary work and a lot of sports activities where people actually 
can participate, makes it looks, I would say, pretty good or better than maybe in another country. 
(Phy5)  
An academic pharmacist linked the future with the blockade and the need to have a 
comprehensive national medicines policy: 
I think more and more, especially after the blockade, the political issues related to the medicine 
sector the way I see the future, because more and more the State of Qatar understand the 
implications and now there are in place emergency preparedness strategies. I am also 
anticipating the realization of the lack of national medicine policy, which is apparent will result 
now in the emergence of one in the State of Qatar. It looks like it is going to be imminent. (AP2) 
A hospital pharmacist also emphasized the need to focus on local manufacturing of medicines to 
secure the future: 
So the future should be good in terms…but we require real experts to work on this. So what I could 
say is they have to be self-sufficient. In Qatar, we have, I think, after a couple of pharmaceutical 
companies. Okay, so first thing is being self-sufficient; you need to manufacture medications. 
Once you have this, 90% of the problem is resolved. (P2)  
A pharmacist in the hospital linked the future to an emphasis on mental health and elderly 
people: 
I will refer here to the Qatar national health strategy, which is covering the next five years. This is 
like the second launch after the one finished before the five years, and now we are more focusing 
on a specific area and the strategy like a mental health, elderly people's…so overall, I think we are 
moving in the right direction in terms of health and medication utilization in Qatar. (P4)  
However, a pharmacy manager at a community pharmacy did not share much optimism for the 
future:  
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I am from sixteen years here. I did not see like significant improvement, and so I did not expect in 
this coming three-four years. I think that we are copying the previous years and we are working 
in the same way. (PM1) 
4.6.2 Future Access and Use of Medicines 
A number of participants believed that in the future, use and access to medicines would improve, 
though an academic pharmacist stated that cost would be a hurdle for improvement in 
community pharmacies: 
It will have to see if government wants to see and force the changes in community pharmacies 
they need to do, not just force but to give them incentives, because I think this is the major issue, 
the cost. Lot of pharmacies don’t wanna make improvements because it's gonna cost them 
money, and if there is some sort of incentive that government can work on to help to make that 
process of change happen, we could see the practice of pharmacy advance. (AP1)  
A manager at a community pharmacy expressed his view in the following manner. 
I wish by these increased standards of practice the incidents of wrong medication, the incidents 
of incomplete medications or compliance, will improve very much through proper pharmacy 
counselling. Yeah, just like in the Canadian health sector and as well as US health sector found 
that the community pharmacists can play a pivotal role in changing the health outcome as well 
as health practice in a nation. Yes, I see even with the Qatar National Vision, the health vision, 
they have included the community pharmacies with a great importance and hope they will rise to 
this vision. (PM2) 
A registration and drug pricing manager referred to the importance of national manufacturing: 
Having more plants locally is very important because, you know, the development of the country 
and increase in the population. For this, we need to by developing and amending the policies, you 
know, to cope with this development of the country. (RDPM1)  
An academic pharmacist at the university stated that the Qatar healthcare system has improved 
in terms of efficiency:  
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I think the State of Qatar has taken so many strategies and initiatives in terms of expanding and 
improving the health sector, and that comes also with a lot of the national health policies and 
strategies or plans or health care plans for the country. We have seen the Qatar National Health 
Policy 2016, which has passed and now we have the new one that started in 2018, I think until 
2022, the National Health Strategy. The statistics of Qatar clearly articulated the direction of the 
healthcare system for the country and I do strongly believe, because the government take this 
issue seriously, therefore, I expect to see a lot of changes in the healthcare system in terms of 
improving efficiency, in terms of improving quality in the healthcare sector. (AP2) 
A hospital pharmacist pointed out that medicines use will increase in the future in Qatar and 
hence, policies and regulations need transformation. He stated this in the following manner: 
Medication use will, I mean, as the population grows more, there will be more use of medications. 
However, I think how we use them, what we use, needs a change. There needs some 
modernization in terms of policies, procedures and regulations in the next three to five years on 
how we use those medications. (P1)  
A hospital pharmacist also expected improvement in medicines regulation and regarding the 
overall use of medicines: 
Depends on the initiatives, to be honest, that are going to be taken by the ministry and the 
government and so on. I think it will improve from one side. I think nationally, there might be 
developments on vaccine use, controlling antibiotics use, promoting certain lifestyles. I think, on 
that perspective, the medicine use hopefully will be better and also because of the budget 
constraint, e.g. that might lead organization institutions to, you know, think about the medication 
use and the financial aspect as well. So I think hopefully it will further improve in the coming years. 
(P5)  
A drug supply Manager emphasized the need for research on genetic diseases and rare disorders: 
I think Qatar will be one of the countries that will be a research target from the manufacturers, 
because in Gulf in general, the rate of rare disease might be more prevalent due to a marriage 
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between the families and those kinds of things. So the genetic diseases might be of interest for 
some manufacturers to come here and test the medicines. (DSM1)  
A hospital pharmacist mentioned more pharmacy involvement in clinical areas: 
I think also things are moving in the right direction. We see more and more pharmacy involvement 
in clinical areas. Initially, like our in-patient area now, we are expanding to, like an ambulatory 
service. Also our rules and policy guidelines has also expanded, which is I'm sure that will all reflect 
on medication use in Qatar. (P4)  
A few participants thought that the government should invest more in drug development. A 
physician in a hospital stated this in the following manner: 
So I mean, an idea I had is, well, let government get into the drug business; let them be willing to 
assume the risk, is essential. At the end of the day, research grant may not see any return on their 
investment. (Phy3)  
This is what a drug supply supervisor said regarding the national health insurance and the use of 
medicines: 
Well, I'm not sure because we have been hearing about some changes in the insurance and 
regarding Qataris and expatriates, and this definitely will affect medication use; and nowadays, 
some hospitals are going to generics and alternatives because some patients definitely will not if 
insurance is minimized or affected by the changes. There will definitely be a change in medicine 
use. (DSS1)  
A hospital pharmacist also emphasized the need for implementation of a generic medicines 
policy:  
The future depends upon, as I told you, they need to introduce generics, so if once they introduce 
generics, the cost wise it will be quite good. And in the same time, it has to be linked to the 
research activities to see whether there is a benefit of introducing generics or not. (P2)  
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The following is the opinion of an academic pharmacist regarding frameworks and strategies in 
relation to access to and use of medicines: 
I would expect more restriction and more control, and I hope for that. Yeah, in terms of medicine, 
there's still more work that has to be done, but I'm sure that Ministry of Public Health is really 
working on strategies and frameworks. I am sure they are working on frameworks and strategies 
in relation to access to medicine and ensuring optimal use of medicines. (AP3) 
4.6.3 Research Ideas for the Future 
A physician stated the need to emphasize policies related to import and export of medicines: 
I see we need to more work about organizing policies for importing and exporting some medicines 
and hopefully, this will be much…with some, all health services and health institute, academics or 
service…do much together and came with one plan and one policy. (Phy2)  
A physician at the university emphasized the need to implement quality control on medicines 
guidelines, as well as on publications: 
Future research, I think what needs to be done before that is maybe just to implement the quality 
control system regarding how the current clinical guidelines are followed. I think this would be 
the most important development for me. Yes, this has to be done. Maybe you can say research 
on quality control, not only the publications because others have done that before, but it can have 
a huge impact on society. (AcPhy1) 
A number of participants suggested more research should be done on community pharmacy. An 
academic pharmacist stated this in the following manner: 
One is they need to do more research on advancing community pharmacy practice. So I think it's 
gonna be a must, and the other thing is that they need to have more focus on educating the public 
about proper use of medicines. (AP1)  
A senior nurse manager at the hospital indicated a need to conduct research on public 
engagement of pharmacies in their local areas: 
I think it would be interesting to see, and this isn't like hardcore research, but on average, how 
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many pharmacies the families use because I go to the same pharmacy all the time, but how many 
pharmacies do people generally go to. Do they have a consistent pharmacy? Do they have 
relationship with their community pharmacist? Do they see it in that way that they have a 
community pharmacist? (SNM1)  
A physician also suggested research should be conducted on issues related to “use of medicine 
at community level” and “over the counter medicines”: 
So again, it's a very wide area; every area needs exploration and research and various levels of 
research are ongoing, but my suggestion would be that the area which needs more attention and 
where generally little work is done [is] the use of medicine at community level and review the list 
of over the counter medicine. (Phy4)  
Additionally, a pharmacist at the hospital pointed out the need to do research on pharmacists’ 
education and counselling: 
I like to assess the quality of pharmacist education and link to patient in terms of counselling, 
directions that they give them and reassess some standards; I think it could be quite variable right 
now. (P1) 
A few participants showed interest in research on health outcomes and the use of medicines. A 
pharmacist working in the hospital emphasized the need for medicines outcome research in the 
following manner: 
I think the outcome research will be nice to see about more research in terms of outcome. What 
outcomes are being achieved with certain use of medications? Whether there is positive outcomes 
or negative outcomes. I think that will be interesting to see, specifically, you know, specifically for 
the national population. (P5)  
An academic pharmacist indicated the need to work on the “socio-behavioural aspect of health 
and the use of medicines”:  
There is more research that needs to be done related to the socio-behavioural aspect of health 
and medicine, the area of health economics, as well as outcome-based research, 
whereby…because at the end of the day, no matter how efficient your healthcare system is, no 
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matter how good you are in terms of accessibility and availability of medicine, it has to stem down 
to what are the outcomes. (AP2)  
Our patients doing better, our quality of life of patients or individuals living in Qatar is better with 
this better healthcare system, so more research needs to be done even at that level in terms of 
health outcomes, health economics and outcome-based research. (AP2) 
Drug development in Qatar was another topic which was raised. A drug supply manager stated 
this in the following manner: 
…that is to see the research on the opportunity of national drug development, maybe not for the 
Qatar only but in the region. What is the future of the drug development in the region here, 
especially in the Gulf specifically, because the Ministry of Public Health can fund this and they 
have some fund for this. Like we can research that for future development of drugs from scratch, 
patent medication to be initiated for the whole world. (DSM1)  
An academic pharmacist mentioned that more research is needed on healthcare and medicines 
policy overall: 
Yes, one is focusing on medicines use, but to me, it's all about surrounding the same issue. I think 
there is more research needs to be done in terms of, in all areas, in terms of policy. Ok, there is 
need for more research in terms of policy, policy of medicine and policy of healthcare policy 
because there is limited literature in that aspect. (AP2)  
The academic pharmacist also suggested the need to have a large database to conduct robust 
research: 
We do not have large databases for doing research in the State of Qatar. So when you want to do 
research, you have to do research at micro level instead of doing research at macro level and 
national level because there are no existing databases, large databases, whereby the whole 
country is connected, where you can collect data and look at issues in a broad context for the 
country. So maybe that's an area also where government can look into establishing those kind of, 
I would say, infrastructure for doing research. (AP2) 
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In summary, these results show that there are issues in relation to non-availability of a 
comprehensive national medicines policy for Qatar, medicines registration, import and 
availability of medicines, high-cost medicines, extended community pharmacy services, antibiotic 
use, medicines compliance, patient counselling and centralized health data in Qatar. The results 
in this chapter have explored myriad and detailed policy issues in Qatar. It is hoped that the 
resolution of these issues could improve medicines use and access indicators in the country. 
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Themes Subthemes Details 
Priority Medicines 
Policy Issues for 
Qatar 
 
Understanding of Priority Medicines 
Policy Issues 
Description of priority medicines 
policy 
Availability of a national medicines 
policy in Qatar 
Current Medicines Policy Issues Issues in finding and following the 
medicines policy 
Medicines registration for Qatar  
Procurement of Medicines and 
Medicines Supply Chain 
Import of medicines  






Process of high-cost medicines for Qataris and expatriates 
Current issues about access to medicines 
Need for further research  
Use of Medicines 
for Qatar 
 
Use of medicines 
Present issues related to the use of medicines 
Challenges and opportunities regarding the use of medicines 
Future research on the use of medicines 
Future Overall 
Health and Use of 
Medicines for 
Qatar 
Overall health issues in the next 3 to 5 years 
Future access and use of medicines 
Research ideas for the future 
Table 3. Themes and sub-themes 




The objectives of the study were to identify priority medicines policy issues for Qatar. The specific 
objectives were to explore and identify key challenges affecting Qatar in terms of priority 
medicines policy issues, including medicines use and access, and to explore what the future 
approach should be in terms of overall health and medicines use in Qatar. In this section, the 
results outlined in Chapter 4 will be discussed in relation to the literature. 
Literature review encompasses large portions of access and medicines use policy components. 
This includes imports and use of medicines, pharmaceutical system issues, and the broader 
medicines policy components. As there is no “definitive medicines policy in Qatar”, these 
different components form into a “medicines policy framework”. The issues identified in the 
literature review have informed the research aim “identifying priority medicines policy issues for 
Qatar”. The literature review themes identified have also been the basis of key questions in the 
semi-structured interview guide. 
The literature covered the various facets of national medicines policy globally. It includes 
examples from both public and private healthcare sectors and the use of medicines. The topics 
include medicine development, manufacturing, marketing, distribution, pricing and 
reimbursement, formulary management, patient eligibility, prescribing practices, and access and 
affordability of medicines. The literature on the use of medicines includes pharmaceutical 
services, pharmacovigilance, and patient counseling, and medicines adherence. There are also 
several articles on the development of national standard treatment guidelines, selection of 
essential medicines pricing policies, allowing price competition, supporting bulk procurement, 
implementing generic medicines policies, negotiating fair pricing, and promoting local 
production.  
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The literature also includes sustainable financing, out-of-pocket expenditures, increased public 
funding, expansion of health insurance schemes, and exploration of external funding and 
financing mechanisms.  
Also, there is a growing number of articles on Qatar’s healthcare system and various dimensions 
of pharmacy services and medicines policies. The literature reveals the community pharmacy 
services are more “traditional” in Qatar, most involved dispensing and pharmacists spend less 
time on counselling patients. It also explores vital issues related to medications nonadherence 
and its impact on health outcomes in Qatar. The literature also outlines challenges faced by 
pharmacists including access to medical records, and pharmacist’s overall image in society. The 
literature highlighted the need to emphasize pharmacists growing role to reduce morbidity, 
mortality and to improve patients’ safety in Qatar. Several articles also reported the need to have 
increased pharmacy staffing, and to promote education and training for pharmacists.  
The participants in this study emphasized that the national medicines policy is instrumental to 
develop the health system. They described the various components of the policy and this is in 
line with the findings from the literature. These components include regulations, guidelines, 
governance, access, and rational use of medicines. As no comprehensive national medicines 
policy is available in Qatar, the work needs to be done in this direction. Some specific components 
with difficulties include medicines registration; however, there is fast track medicines registration 
process, and a special import process for some medicines in MoPH. There were also interesting 
results coming up with regards to the funding of medicines as in Qatar, health services are free 
for Qataris. For non-Qatari residents, the services are subsidized.  
The participants identified issues with regards to the use of medicines and the challenges related 
to community pharmacists providing optimal patient counselling for medicines. These factors 
may contribute to nonadherence and misuse of medicines. There could be issues with regards to 
the rational use of medicines as patients have several prescribed medicines and have access to 
over counter medicines at home. There are also because some classes of therapeutic medicines 
are available without a physician's prescription. On the other hand, some participants also 
suggested that because there is no national computerized healthcare database, community 
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pharmacists and other healthcare providers do not have access to vital patients' health status 
and electronic health records. This could lead to prescribing errors and “medication management 
issues”. From the literature, it was also noted that these medicines use issues are very similar in 
the countries with developing health systems.  
5.1 What is Medicines Policy? 
The study showed that the participants’ understanding of medicine policy is dependent upon the 
area in which they practice. One participant believed that medicines policy is about procuring 
medicines, medicines prescribing and adverse events related to medicines. Though this may be 
correct, medicines policy covers more than medicines prescribing. Caijun et al. (2020) maintains 
that a medicines policy should work as a legislative framework to control medicine development, 
manufacture, pricing, medicine supply systems, medicine financing, quality assurance, use of 
medicines, research, human resources, monitoring and evaluation.[32, 50, 141] However, 
Morrow (2015) explains the utilization of a healthcare system simply as a means to achieve 
improved health outcomes.[79]  
5.1.1 Access to Medicines Policy  
The research also showed that most participants were not aware of Qatar's medicines policy and 
suggested that a medicines policy may be available from the Ministry of Public Health. However, 
the literature shows that Qatar’s national medicines policy is neither available nor published. 
However, there is a National Health Strategy 2018.[6] It was observed that Qatar's national 
medicines policy is not available as one single document, but is an amalgamation of a set of 
regulations, procedures, rules, strategies, control processes and standard operating procedures 
(SOPs) regarding the use of and access to medicines.[23]  
5.1.2 Issues Related to Finding a National Medicines Policy  
Most participants pointed out the lack of a comprehensive national medicines policy in Qatar. 
There are rules and regulations, but they are not clear, do not provide details and are not 
updated. Some of the regulatory documents are not translated into English, which is challenging 
for non-Arabic participants. Other participants added that in Qatar, being a multicultural society, 
there are people from different backgrounds. Therefore, it is imperative to have a medicines 
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policy that includes rules and regulations so that healthcare professionals can understand and 
benefit from it. In Australia, McLachlan and Aslani (2020) also suggested that a national medicines 
policy should include issues related to biologicals and biosimilars, precision medicines, health 
services insurance and issues related to the pharmaceutical industry.[142]  
5.1.3 Medicines Registration in Qatar 
The findings showed that some participants could not find a written policy for the registration of 
medicines. Another issue is that due to the blockade, it took some pharmaceutical companies at 
least nine months to register a medicine. Moreover, even post-Qatar blockade, it may take four 
to six months, although there is fast-track registration for specialized medicines, including blood 
products and any medicines required urgently. The research also revealed that a pharmaceutical 
product must be registered in Qatar every time someone decides to bring the product into Qatar, 
and the detailed registration procedure and requirements are available on Qatar's MoPH 
website. All pharmaceutical product registration is under the Ministry of Public Health in Qatar. 
The registration process includes the registration of a company and the manufacture of 
pharmaceutical products.[35] Hamad Medical Corporation (HMC) also has a particular procedure 
to procure needed medicines. This is done by directly contacting the authorities in other 
countries, including embassies and manufacturers, to purchase these medicines.  
5.1.4 Import of Medicines for Qatar 
The import of medicines in Qatar depends upon product prices, market size and competition. All 
medicines registered by MoPH, and medicines pricing, are regulated by Ministry of Public Health 
(MoPH). The literature shows that Qatar’s pharmaceuticals sector is very much reliant on imports 
of pharmaceutical products. The government is trying to eliminate price controls that have 
affected consumer affordability.[10] After the blockage in 2017, Qatar developed new alternative 
suppliers for medicines and successfully overcame the medicines supply challenge.[7] Overall, 
the import of medicines has challenges, including the fact that the registration process is time-
consuming and complicated. 
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Manufacturing of Medicines in Qatar  
Qatar Pharma was the first company to start local manufacturing. After Qatar's 2017 blockade, 
more local pharmaceutical companies began planning to start operations. Some companies are 
still in the planning stage, including Qatar Al-Hayat, Q-Med, Al-Mutamayyiz pharmaceuticals and 
Doha factory for pharmaceutical products. There was a need to reduce dependence on imported 
pharmaceuticals.[38] Qatar Life Pharma is another domestic pharmaceutical manufacturing 
company. It was started in 2014 and is working to get FDA USA approval.[32] Another company 
starting local manufacturing is the Qatar Pharmaceutical Industries Company.[39]  
Understanding Access to Medicines 
5.1.5 Process of High-Cost Medicines for Qataris and Expatriates 
The research reveals that both Qataris and expatriates have access to the healthcare system and 
medicines. Qatari citizens do not pay for their medicines, while expatriates pay only 20% of the 
medicine’s price in the public sector and Qatar's government pays 80% of it. For cancer 
medicines, expatriates pay only 10% of the price of medicine. The expatriates pay for medicines 
from their health insurance coverage or from their own pocket. There is a National Health 
Insurance Scheme for all Qataris, which pays for all their healthcare services and medicines in the 
public and private sector. The government of Qatar is planning to offer the National Health 
Insurance Scheme to expatriates too.  
Additionally, there are support systems available for expatriates to pay for medicines, including 
expensive medicines; non-profit organizations, for example, the Multiple Sclerosis Society, Red 
Crescent and other charity organizations support expatriates. The medicines pricing method in 
the public sector is not publicly available, but medicine prices in the public sector are noted to be 
considerably lower than in the private sector.[23] The Ministry of Public Health (MoPH) controls 
medicine pricing. The Pharmacy and Drug Control Department (PDCD) negotiate with 
pharmaceutical companies and other stakeholders to propose prices for medicines, and the 
MoPH has the authority to fix the prices.[10] Overall, Qatari nationals and expatriates have access 
to high-cost medicines in Qatar. Challenges with high-cost medicines are a global phenomenon, 
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and they present health and economic challenges for healthcare organizations. These include 
affordability, decision-making, reimbursement and coverage of these medicines.[92] 
5.1.6 Issues with Access to Medicines in Qatar 
The participants have the opinion that overall, consumers and patients have access to a large 
number of medicines in Qatar, though there are issues with a few medicines. Specifically, the 
public sector in Qatar has a satisfactory level of availability of medicines,[143] but the issues 
mentioned included inconsistency of the medicines supply, limited range of some classes of 
medicines, and the fact that not all registered medicines are available. The research revealed that 
many companies are not registering their medicines due to the small market size. However, the 
Ministry of Public Health (MoPH) is working to formalize the National Formulary. Additionally, 
the participants revealed during interviews that labourers have a different level of access to 
medicines in the private sector because of the different co-payment method for health insurance 
plans. 
The majority of medicines are available over the counter at pharmacies in Qatar for the public. 
This increases the pharmacist's role in improving the optimal use of medicines.[9] However, the 
research shows that there are misconceptions about the use of generic medicines, both among 
clinicians and among the public.[31] Therefore, the clinicians are reluctant to prescribe, and 
patients do not trust, generic medicines and prefer the branded products which are more 
expensive options.  
The findings revealed that patients must return to the pharmacy quite often to pick up narcotic 
and psychotropic medicines due to stringent regulations which result in dispensing of smaller 
quantities medicines. Due to the absence of a standard national medicine policy, there are 
discrepancies and inconsistencies in how different organizations work to provide access to 
medicines.  
The results also revealed that there are medicine affordability issues, especially in Qatar’s private 
sector. This is specifically the case in the area of high-cost medicines for expatriate patients. 
Furthermore, in the context where some of them have employer’s health insurance, patients may 
not be able to pay the co-payment for medicines.[143, 144]  
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5.1.7 Need for Further Research  
The participants stated that they would like to see more research on medicines that are 
frequently being sold without guidance from physicians and pharmacists. Patients may have 
adverse effects from medicines and compare them with other countries. Other participants 
would like to see research on the outcome of guidelines, policy and use of medicines issues.  
The participants would like there to be more research into antibiotic resistance because in Qatar, 
people come from different parts of the world where they have more access, or more controlled 
access, to antibiotics and they have different resistance status.  
During the interviews, the participants identified a need for research on barriers to access, 
availability, affordability and cost of medicines from all perspectives, such as from policymakers, 
clinicians, consumers and others. They also said there were issues around the cost of generics 
and branded medicines, what happened to patients' unused medicines, and why most patients 
expect to receive a medicine prescription at every physician’s appointment. 
5.2 Use of Medicines 
The participants revealed how they would describe the use of medicines, whether looked at from 
the perspective of medicines utilization in healthcare institutions, regulatory authority or the 
consumer perspective. “Use of medicines” includes selection and approval of the prescribing, 
dispensing, monitoring and storage of medicines.[97] The participants also discussed medicines 
from the patient’s perspective, in terms of whether patients are using medicines as prescribed 
or directed with the right dose.[107] 
Present Issues Related to the Use of Medicines 
This study states that a national medicines policy should cover all aspects of policies and 
procedures for medicines. This includes all phases of medication management, including 
antibiotics policy, medication prescribing, adverse drug monitoring, use of medicines, drug 
supply chain, and policy governance in the public and private sectors.  
The participants in the study opined that for most patients receiving medicines, there were 
patient compliance issues such as misuse of medicines or expired medicines at home. Literature 
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from Qatar also confirmed these findings, one study indicating that about 82% of patients were 
using antibiotics without prescription, in 45% of cases the antibiotic course was not completed 
and 23% had purchased antibiotics from the community pharmacy without a prescription.[41] 
Another study concluded that medicine use is impacted by factors involving adherence to drug 
therapy, the duration of chronic disease, diagnosis and control of the disease, as well as patients 
being employed or receiving support from family.[145] Hence it is recommended that a 
standardised national medicines use policy should be formed to improve patient health 
outcomes. 
5.2.1 Challenges and Opportunities for the Use of Medicines 
The results suggest that there are policies and guidance with regards to the use of medicines in 
Qatar public sector institutions, including Hammad Medical Corporation (HMC), Sidra Medicine, 
and others; however, not all private institutions have clinical guidelines. Also, there is no national 
health record database for all patients' health information which can be accessed by healthcare 
providers, public and private institutions, hospitals, clinics and pharmacies. A national medical 
database would help to improve the use of medicines. It would also help to improve and build 
prescribing policies for medicines. Awaisu et al. (2014) concluded that a nationally organised 
project should be started to develop a generic medicines policy, guidelines, and a comprehensive 
national medicines policy in Qatar.[31] Regarding generic medicines use and prescribing, a study 
by Awaisu et al. (2014) found that 89% of Qatar's pharmacists agreed that bioequivalence data 
should be available before marketing a generic medicine. Most also agreed that community 
pharmacists should be authorised to dispense generic substitution of medicines in Qatar.[31] 
This study’s findings show that multidisciplinary team collaboration is another challenge that 
needs resolution. There are also challenges with regard to other issues, including prescribing of 
antibiotics, pharmacovigilance system implementation, and generic medicine availability and 
prescribing.  This is supported by a study in Qatar which revealed that 75% of pharmacists and 
50% of physicians do not provide sufficient patient education on antibiotics use in the 
country.[41] Aljayyousi et al. (2019) concluded that there is a need to increase public education 
about appropriate antibiotic use and to emphasize behavioural interventions.[41] The study 
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further concluded that health institutions should educate healthcare practitioners about 
antibiotic prescribing, guidelines and better communication methods.[41] 
5.2.2 Pharmacoeconomics Research 
The results of this study showed that there is a need for pharmacoeconomic research to evaluate 
the cost-effectiveness of use of medicines. More research is also needed on procurement and 
availability of medicines. Furthermore, the participants suggested that studies are also needed 
on wastage of medicines. 
Overall Health in Next Few Years 
The participants believed that health indicators will improve in Qatar in the next few years. This 
is because the State of Qatar has implemented emergency preparedness strategies, including 
strengthening of regulatory agencies, as well as the strengthening of ministries including the 
Ministry of Commerce and Ministry of Public Health, and the focus is now on the medicines 
sector. In addition, the study’s results revealed that Qatar is starting national pharmaceutical 
manufacturing; hence there is a chance that the country is on the road to self-sufficiency in 
medicines supply in the next few years. Qatar's primary care services model is effective. It 
appears that in the next few years, the Qatar healthcare system will continue to improve because 
of the National Health Strategy 2018-2022 and Qatar National Vision 2030.[6]  
However, Qatar still needs improvement in antibiotics prescribing, access, patient education and 
public awareness. Aldeyab’s (2020) research shows that antibiotic resistance could be controlled 
by understanding the thresholds for all antibiotics used in a country and forming an antibiotic 
policy.[98] A study conducted in Qatar also showed that the public believes antibiotics can be 
used for viral infections. This could lead to inappropriate use of antibiotics and increased cost; 
therefore, community pharmacists should play an active role in improving knowledge and public 
views about antibiotics.[117]  
5.2.3 Community Pharmacy in Qatar 
The community pharmacy services provided are mostly “traditional” with no extended 
pharmacist roles or cognitive services in Qatar. Community pharmacy has not developed the 
essential steps to be recognized as an essential source for public health and primary health 
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care.[9] Babiker et al. (2014) also concluded that pharmacists need more education and training 
for medicine use reviews in Qatar.[101] Babar (2021) explains that to improve community 
pharmacy, training in clinical skills and patient-oriented pharmacy services is needed.[146] 
Private community pharmacies in Qatar also need to be involved in the government health 
coverage system to improve the affordability and access of medicines.[146] In developed 
countries, most pharmacists are remunerated for pharmacy services they provide; however, this 
is not the case in many countries including Qatar.[109] More research is needed in Qatar to 
identify challenges in developing community pharmacy and how to overcome those difficulties, 
as well as how to improve communication with patients.  
5.2.4 Future Use of Medicines and Community Pharmacy 
This study indicates that community pharmacy has the potential for improvement and practice 
change, and more research is needed in this context. The Qatar National Vision 2030 and National 
Health Strategy 2018-2022 both include the community pharmacy's importance; hence 
community pharmacy services could be improved in the coming years.[6] The participants in this 
study suggested that there is a need to have modern policies, procedures and regulations related 
to community pharmacy in the next few years.[21] The cost of medicines is increasing, putting 
pressure on the healthcare budget. This needs more scrutiny of medicines to use, as the use of 
generic medicines would reduce the total cost of medicines in Qatar. The literature illustrates 
that there is inconsistency in executing generic medicines policies between developed and 
developing countries, and where generic medicines are used there are considerable savings on 
medicines.[121].  
5.2.5  Future Research Ideas 
The suggested future research areas include the quality of clinical consultations, pharmacists 
providing counselling and advice to patients, and reassessing clinical guidelines. Other research 
areas could be outcome research, use of medicines among nationals and expatriates, and the 
availability of over-the-counter medicines at community pharmacies in Qatar. One of the 
participants also suggested creating large medicines databases for research. This could help in 
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looking at critical areas including population demographics, medicines utilisation, disease burden 
and consumer use with regards to medicines [52]  
A conceptual model has been built to identify and synthesise priority medicines issues arising 
from this work (Diagram 1). “Healthcare practitioners” and “academics” are feeding into this 
model and their thoughts, ideas and knowledge are shaping the model. As shown below, the 
outer circle of the model represent “broader healthcare” and “public policy”. The main issues 
arising from this model include (a) extended community pharmacy services; (b) antibiotics use, 
medicines compliance and counselling; (c) access to high-cost medicines for Qataris and 
expatriates; (d) issues related to medicines registration, import and availability of medicines; (e) 
forming a comprehensive national medicines policy for Qatar; and (f) centralised health data for 
patients, pharmacists and healthcare professionals. 
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CHAPTER 6 
6 Conclusion  
The research concludes that though there is no comprehensive national medicines policy in 
Qatar, there are a number of rules, regulations, policies and procedures in place. There are 
challenges in following and understanding these policies, as they are not available as a single 
document. The access issues identified include availability of medicines, inconsistency of 
medicines supply, limited range of some classes of medicines, and the fact that not all registered 
medicines are available. There are misconceptions about the use of generic medicines among 
clinicians and the public. There are instances when clinicians are reluctant to prescribe and 
patients do not trust generic medicines, resulting in increased cost for patients. The challenges 
with regard to medicines use include prescribing of antibiotics, pharmacovigilance system 
implementation, and generic medicines availability and prescribing. The community pharmacy 
services provided are mostly “traditional”, with no extended pharmacist roles or cognitive 
services. There is a need to extend the role of the pharmacist and this can be done by providing 
financial incentives, education and training for pharmacists, as well as improvement in policies, 
procedures and regulations. This also includes authorisation to dispense generic substitution of 
medicines. There is also a need to have a national health record database for all patients' health 
information, which can be linked to healthcare providers, public and private institutions, 
hospitals, clinics and pharmacies.  
Future research areas to focus on include quality of clinical consultations, pharmacists providing 
counselling and advice to patients, and reassessing clinical and therapeutic guidelines. Other 
research areas could be outcome research, use of medicines among nationals and expatriates, 
and availability of over-the-counter medicines at community pharmacies in Qatar. 
The main aim of this research was to identify and explore priority medicines policy issues 
impacting Qatar. These objectives were explored and achieved through a series of semi-
structured qualitative interviews. A thematic analysis was performed and main themes were 
identified. An overarching theme was also identified that though respondents know components 
of national medicines policy, however, they were not aware of an existing medicines policy 
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document. From literature, it is observed that over 100 countries in the world have developed a 
national medicines policy which has led to improve medicine use in respective countries. 
Medicines are an essential component of a health system and from the findings of this thesis, it 
is believed that the formation of such a policy would also benefit Qatar and would improve 
healthcare in the country. 
Implications for policy and practice 
This study has achieved its objective by identifying vital issues related to medicines policy, access 
and use of medicines, future overall health and use of medicines. The study has identified 
empirical data points, which have formed and fed into a conceptual model. Vital research points 
are coming from medicines use and access, if implemented these can improve patient health 
outcomes and can improve the use of medicines in the country. 
6.1 Limitations and Strengths of the Study 
For many of the participants, English was not their first language. In addition, of the 55 
stakeholders who were contacted and invited, only 21 participated in the interviews. This may 
have limited the range of stakeholders by not including patient support groups or the 
pharmaceutical manufacturing sector, who did not participate in this study. However, despite 
these limitations, the study provides enough data to portray an overall picture in terms of 
medicines use and access. These data add to our understanding of the medicines policy issues, 
and future health challenges and opportunities for Qatar.  
The strength of the study is that it is the first such study on the topic. It emphasizes the various 
facets of medicines policy and provides a comprehensive analysis of policy issues in detail. The 
major themes are covered on medicines use and access situation in Qatar, including community 
pharmacy practice, medicine registration, patients counselling , medicines access, and medicines 
adherence issues. 
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6.2 Recommendations 
The findings suggest that in the last 20 years Qatar has moved towards advancing healthcare, 
however, there are gaps and opportunities. These are quite pertinent with regards to improving 
medicine use, access, and developing a medicines policy in Qatar. 
A national medicines policy should be developed through a consultative broad-based process in 
which prescribers, physicians, pharmacists, and healthcare professionals be given a chance to 
contribute. A framework should also be developed regarding the implementation, monitoring, 
and evaluation of this medicines policy. 
Based on these study findings strategies need to be developed to resolved access to medicines 
issues, the priority being medicines registration, import etc  
With the rise of chronic diseases and a growing population, there is also a need to work to 
improve medicines adherence among patients. The strategies need to be developed on patient 
counseling. There is also a need to improve professional training and continuing education for 
pharmacists to advance pharmacy practice.  This would help to improve medicine use among 
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7 Appendices  
7.1 Appendix 1 





Invitation Letter:  MSc Research - Priority Medicines Policy Issues for Qatar: Challenges and 
Opportunities. 
 
My name is Nadeem Zia, and I am serving as a Clinical Pharmacist, Pharmacy Department 
Educator, Department of Pharmacy, Sidra Medicine, Doha, Qatar. As a health care professional, 
my research team and I am very much interested in the priority medicines policy issues for Qatar: 
challenges and opportunities.  
Therefore, in collaboration with the Centre of Pharmaceutical Policy and Practice Research, 
University of Huddersfield, UK, and Qatar University College of Pharmacy, a qualitative study is 
planned to explore the priority medicines policy issues for Qatar: challenges and opportunities.  
For that purpose, our team identified you as an important and influential stakeholder with 
interests and experienced relevant to the aim of this study and would like to humbly request you 
for a 60-minute interview session personally. The benefit of participating in the study is that we 
will have documented the opinions and views of influential stakeholders about the priority 
medicines policy issues for Qatar. 
Please let us know by replying to this email as soon as possible if you agree to participate. The 
interview will be in English. An interview guide will be sent to you by email prior to the mutually 
agreed date and time of the interview session.  
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Confidentiality: All the information we receive from you, including your name and any other 
identifying information (if applicable), will be strictly confidential and will be on a password-
protected server. We will not use any information that would make it possible for anyone to 
identify the opinions you contributed to the interview session. The interview will be recorded so 
that a comprehensive transcript can be produced. Digital files of the recordings will be destroyed 
upon completion of the transcript approximately 7-10 days after the call, and names and other 
identifying information will be deleted from all electronic and paper copies of transcripts.  
 
If you have questions about this project, you may “reply” to this email, and we will respond to 




Nadeem Zia, B Pharm, PEBC, RPh,  
 
Pharmaceutical Sciences MSc (Research) Candidate,  
University of Huddersfield, UK   
Clinical Pharmacist - Pharmacy Department Educator, Sidra Medicine, Qatar   
 
Supervisors:   
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Professor. Mohamed Izham Mohamed Ibrahim, Head of Research and Graduate Studies - 
Pharmacy, Medical & Health Sciences Office Professor of Social & Administrative Pharmacy 
College of Pharmacy, Qatar University, PO Box 2713, Doha, Qatar. 
 
Professor. Zaheer-Ud-Din Babar, Professor in Medicines and Healthcare 
Department of Pharmacy, University of Huddersfield, Queens Gate, HD1 3DH, Huddersfield, 
United Kingdom 
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7.2 Appendix 2  
Interview Guide – Semi-Structured Interview Guide 
Research Title: Priority medicines policy issues for Qatar: Challenges and opportunities 
 
1. Priority medicines policy issues 
1.1 Can you please describe the "medicine policy"?   
1.2 Where can someone refer to the medicine policy in Qatar? 
1.3 What are your views about the priority of medicines policy issues in Qatar? 
1.4 Are you aware of any scheme or procedure to enhance support for the development or 
import of medicines that target an unmet medical need? 
1.5 Is there any support available to medicine developers or importers in Qatar? 
1.5.1 To optimize the generation of robust data on medicine's benefits and risks. 
1.5.2 To enable accelerated assessment of medicine applications. 
1.6 What kind of assessment does a newly developed or imported medicine (on the priority list) 
go through before, or at the time of, application for marketing authorization (registration)? 
1.7 Are there any regulatory frameworks or tools already available for accelerated assessment 
(for medicines on the priority list)? 
1.8 Is there any national policy on the use of medicines and access to medicines in Qatar?  
1.9 How does the Qatari government or health authority deal with priority medicines policy 
issues? 
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2. Access to medicines in Qatar  
2.1. What is your general perception of access to medicines in Qatar?  
2.2. How do Qatari nationals and expatriates get access to (high cost) medicines?  
2.3. What are the issues surrounding access to medicines in Qatar? 
2.4. Is there enough evidence (literature or data) on these issues to make decisions in Qatar? 
2.5. Is there any other issue or question which you think should be researched?  
3. Use of medicines in Qatar 
3.1 Can you please describe the use of medicines?  
3.2 What are some issues related to the use of medicines in Qatar? 
3.3 What are the challenges and opportunities in the use of medicines in Qatar? 
3.4 What are the medicine policy issues on the use of medicines in Qatar? 
3.5 What type of research would you like to see on issues related to the use of medicines in 
Qatar? 
4. Future of overall health and medicines use in Qatar 
4.1 How do you see the future in terms of overall health in Qatar in the next 3 to 5 years? 
4.2 How do you see the future in terms of medicines use in Qatar in the next 3 to 5 years? 
4.3 What are the issues related to access to medicines in the next 3 to 5 years?  
4.4 What type of research would you like to see on issues related to future overall health and 
medicine use in Qatar? 
 
Nadeem Zia, B Pharm, PEBC, RPh  
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Pharmaceutical Sciences MSc (Research) Candidate 
University of Huddersfield, UK 
Clinical Pharmacist - Pharmacy Department Educator, Sidra Medicine, Qatar  
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7.3 Appendix 3  
Ethics approval letter form, University of Huddersfield, UK. 
 
School of Applied 






14th May 2019 
 
Dr Syed Shahzad Hasan 
School of Applied 





Re: Priority medicines policy issues for Qatar: challenges and opportunities (Nadeem Zia) 
Thank you for submitting your proposals to the School Research Integrity and Ethics 
Committee (SRIEC). I am happy to confirm that the project has been approved from the date 
of this letter up to and including the 7th January 2021 as indicated on the documents 
submitted. 
We note that the study will be conducted in Qatar and whilst we have given approval for the 
project based on the project specific details as presented here, there maybe specific 
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requirements that need to be met by your partners in Qatar. It is therefore incumbent upon 
you to ensure that appropriate permissions are obtained prior to the start of the project in 
Qatar. Based on the study design however, we are happy that this does not raise any significant 
ethical concerns regarding the questions being asked or the handling of any data. 
 





Professor Roger M Phillips BSc, PhD, SFHEA 
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7.4 Appendix 4 
Ethics approval letter form Sidra Medicine, Doha Qatar. 
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7.5 Appendix 5  
Ethics approval email from Saad Abdullah, Abhath IRB, Hamad Medical Corporation (HMC), Doha 
Qatar. 
 
 
 
 
 
 
 
 
